Saturday, July 30, 2011

CancerWife had 15 injections of Coley's toxins but then the blog stopped

http://physpharm.ohsu.edu/faculty/PKCore/12x32vials.jpghttp://www.placidway.com/images/679/OOH1_pic.jpg
1.5ml vial with coley's toxins



CancerWife had 15 injections of Coley's toxins
from 9 August 2010 to 9 September 2010
at
Oasis of Hope Hospital Paseo Playas No.19. Playas de Tijuana (aka Contreras Clinic)
in Mexico, $8000 or more

This is a record of the blogreport until CancerHusband's blog stopped...
They got coley's toxins supply and  now are doing it at home by themselves for no money ... and have to keep quite about it because of doctors, pharma FDA mafia.
http://www.google.com/search?q=cancerwife.com

http://images.wikia.com/diabetesindogs/images/4/44/3_10.JPG
0.3ml syringe (originally for diabetes) -- cancerwife did not use a syringe but used a drip, a port, an infusion


The standard  protocol starting dose recommended is  0.001ml


First injection.   (INFUSION actually)

==  DOSE   0.0005ml ==

Coley's Toxins IV #1 - Our adventure begins    
Submitted by CancerHusband on Mon, 08/09/2010 - 21:20

We had brought a large body-sized far-infrared heating pad to warm her, as well as smaller one for her chest. I kept her under blankets and turned up the room thermostat to 80F. We did this to take the edge of the chills and shakes, as well as to reduce energy requirements by the body to raise core temperature.

1.5 hours after infusion, she began experiencing chills. We cranked up the heat, in order to fend off more extreme chills and the shakes. That worked very well. Shortly after cranking up the heat, her chills all but disappeared. Then, 45 minutes after onset of chills, her temperature reached 102.1F.

So then, it seems that our very first infusion, at 1/2 the typical starting dose managed to induce fever! The actual time above 102.5F was probably not more than 15 minutes. So, it wasn't a very strong response, but a good response nevertheless.

Some observations:

    Her pulse peaked at 117
    Her face was flush red
    Her minimum blood pressure was a drop to 102/54 about an hour before the chills happened (during the pre-warming phase)
    She felt some bone pain in the hip and some soreness in the back. These were very minor.

Generally, we felt that our very first Coleys went as well as one could ask for. We achieved fever in the target range and there were no complications! Overall, the entire fever process took about 6 hours, after which she felt 100% back to normal.

==  DOSE   0.0005ml ==

Coley's Toxins IV #2 - Substantial fever attained!  
Submitted by CancerHusband on Wed, 08/11/2010 - 21:46

Today, we stuck with the same 0.0005mL CFIV dosage. We expected that there may not be any fever today because we're using the same dosage as past Monday's. If you remember, Monday's fever broke past the 102.5F barrier for only 15 minutes. Furthermore, the body is supposed to get more tolerant to Coleys so one would expect a lower fever than expected this time.

However.... to our pleasant surprise, today's fever was a robust one. Chills began almost like clockwork at 1 hour after start of infusion (this is what the MBVax documentation also says).

Her temperature hit 102.5F at 45 minutes after onset of chills. Thereafter, the fever was long and robust. In all, it stayed above 102.5F for a full 2.5 hours. Furthermore, it stayed above 103F for over an hour, reaching a peak of 103.5F.

One unexpected side effect today was she experienced a few minutes shortness of breath. We notified the nurse just in case. The nurse seemed to have seen this before and immediately hooked up an oxygen cannula, running at 1.5 LPM.

Generally, we observed that she sweated quite intensely today. This may have been due to the more aggressive pre-warming (higher heat pad settings, higher room thermostat setting, more blankets). To compensate, I made sure that she consumed more oral electrolytes.

So, it would seem that more aggressive pre-warming may potentially have contributed to a more intense generation of fever? An alternate explanation is she wasn't feeling very strong before commencing Monday's first dosage. Perhaps that would be a more apt explanation for today's higher fever (with same dosage).

Summary: Today's was an extremely successful fever. However, we're curious why it was better than Monday's despite staying at the same dose level.

== DOSE 0.0005ml ==

Coley's Toxins IV #3 - Learning to avoid dehydration during pre-heating  
Submitted by CancerHusband on Fri, 08/13/2010 - 21:16

Looking back at today's treatment, we concluded that we have been too aggressive with the heating pads. In our enthusiasm to avoid the chills and shakes that Coley's induces, we've been aggressively pre-heating her to the extent that she began sweating profusely even before the fever started.

This inadvertently led to significant dehydration, which manifested as flushing of face, low blood pressure (as low as 108/43), and requiring oxygen to alleviate shortness of breath.

The doctor had her feet raised and ordered an IV drip of Hartmann Solution to counter the dehydration and hypotension.

She eventually stabilized and the blood pressure rose. Shortly thereafter, she was able to achieve a fever. However, the fever stayed mainly between 101 and 102F. There were only 2 extremely transient peaks where her temperature managed to exceed the 102.5F target threshold. These peaks lasted for a few minutes, dropping thereafter.

It is our conclusion that the significant dehydration probably robbed her body of the necessary energy to mount a proper fever response today. The 2 transient peaks were indicative of her body trying to raise temperature but "running out of steam".

After her fever peaked and died down, she was, as before, able to get up and enjoy a meal. Her appetite was good and she felt normal, except for being a little tired (The picture below is of her enjoying her post-fever dinner).

For the next Coley's, we plan to alter strategy and go easier with the pre-heating. It'll be interesting to see if that doesn't prematurely tire her body out as much, and therefore help her achieve a higher fever.


== DOSE  0.0005ml ==

Coley's Toxins IV #4 - On the right track   
Submitted by CancerHusband on Mon, 08/16/2010 - 21:15

She was rather tired over the weekend. The Issels doctors prescribed IV protein + Magnesium to replenish her (a CBC done on Saturday morning showed that her protein levels had dropped to 5.8 g/dL (normal minimum being 6.0). The doctor had already predicted it may happen before the CBC was done. The doctor said that drops in protein levels may happen when you have fevers. This, by the way, is one of the advantages of doing Coleys at a place that has a long legacy of doing immunotherapy.

Anyway, the doctors think that her tiredness on Sunday was probably due to her body replenishing after the draining fevers. We decided then to stick with the same CFIV dosage (0.0005mL) and see what temperature she'll achieve with less aggressive pre-heating.

As usual, we had our breakfast from 830-930am. However, after last week's experiences, we concluded there was no way that the Coley Fluid infusion would begin on time at around 11am (The MBVax protocol calls for 2 hours of no food prior to start of IV). Thus, I advised her to eat a good breakfast, knowing that she'll have no lunch.

As it turns out, today's Coley's began even later. By the time we got the diluted solution hooked up to her PICC port, it was about 2:00pm. By that time, it was 5 hours after breakfast and she was already getting hungry. I started her on the oral electrolytes to keep her energy up (there's a good amount of sugar in there).

As planned, we kept the heat pad on a lower setting and modulated other variables such as the number of blankets and room thermostat. Our guiding principle was to keep her warm but avoid making her sweat.

Things went slow and there was no indication of chills or fever for quite a while. But about 2 hours after infusion start, her hands began to feel tingly and she felt some light chills. This seemed to be a delayed response as compared to previous weeks, but nevertheless a response. At 4:30pm her temperature broke through to 102.7F and stayed above 102.5 until 6:00pm. As we had hoped for, she experienced no dehydration, no major drop in blood pressure, no need for oxygen, no flushing of the face. We were ecstatic. Furthermore, she only needed to drink a little over 2 cups of the oral electrolyte formula (as opposed to 6 cups last Friday).

Overall, today's fever was a successful one. 1 1/2 hours above 102.5, with a peak of 102.9F. Not a very high fever, but still a good one. One should also note that the fever was significantly higher than last Friday's treatment, although at the same CFIV dose level. This further corroborates our thinking that dehydration robs the body of energy to mount a good fever.

As aforementioned, there were few unpleasant side effects, the primary one being tiredness and fatigue. The main thing though is it seems we've figured out a very important guideline - which is to avoid sweat (and consequently dehydration) during pre-heating.

== DOSE 0.00075mL ==

Coley's Toxins IV #5 - First dose increase (to 0.00075mL)  
Submitted by CancerHusband on Wed, 08/18/2010 - 17:06

Today, we increased the dosage from 0.0005mL by 50% to 0.00075mL. Those of you familiar with the MBVax protocol will note that this is still less than the typical starting dose of 0.001mL. The reason why we're treading cautiously is from previous experience with various drugs and chemo. She just tends to react quite strongly to typical dosages (even those adjusted for body weight).

Coley Fluid infusion started at 12:30pm. The first sign of chills occurred about 45 minutes later. By 3:15pm, her temperature broke through to 102.6F. It stayed there for a little over an hour. The highest point being 102.7F.

Compared to Monday's fever, this one was a tad lower (Monday's highest was 102.9, with 1.5 hours above 102.5 threshold). This may indicate a need to increase the dosage to 0.001ml next.

Also, a new development today was her pulse rate reached a peak of 130 (10 points higher than Monday's highest). This is a first. I notified the nurse who contacted the doctor. The doctor didn't seem concerned but ordered IV hydration. I'm guessing the doctor thinks the elevated pulse is probably due to dehyration.

Overall, she felt pretty good throughout the fever. The primary symptom, again, was fatigue. Again, she had some slight coughing (coming from the diaphragm). The doctor said that it's most likely due to inflammation caused by the fever.

Even though she felt pretty good throughout the fever, she was quite tired out at the end of the day. Not enough energy to go down to dinner so I brought food up from the cafeteria. We'll see how she feels tomorrow.

== DOSE 0.00075mL ==

Coley's Toxins IV #6 - Looks like it's time to increase dosage more aggressively 
Submitted by CancerHusband on Fri, 08/20/2010 - 17:26

Today, it took almost 2 hours before there was any rise in temperature at all. However, she eventually developed fever, although it was clear that the temperature rise was not as fast and as high as previous treatments. She also experienced some light chills at that time.

Three hours after infusion start, she reached 102.6F. This lasted for barely an hour. Also, her peak was 102.7F. She also tolerated the fever very easily and didn't feel much discomfort, except for the fatigue that's always most prominent during fever peak.

As in the past 2 treatments, we kept the heating pads to a minimum and avoided making her sweat before onset of chills of fever. We also observed that she began to sweat during the cool-down phase of the fever (consistent with the MBVax protocol documentation).

As before, the side effects experienced during the fever were

    chills (kept to a minimum using heat pads & blankets)
    achy feeling in hips downwards (intensity 2 out of 10)
    minor one-sided headache (2 out of 10)
    dry cough especially when lying on the side

All the above side effects disappeared after the fever subsided. We also observed something interesting (but not surprising). During the chill phase, if she turned on her side, the shoulder not in contact with the heating pad would start to feel the chills. This would be immediately mitigated by lying on her back against the heating pad.

Again, this fever seemed to be lesser in intensity and duration. By 5 hours after start of infusion, she was all ready to head down for dinner (she never gets to eat lunch during the days when she gets Coleys, mainly to avoid nausea during the fever). She even felt strong enough to take a shower before heading down to the cafeteria for dinner.

Next week, we are considering increasing the dose to 0.002ml. We feel that the increase from 0.0005 -> 0.00075 didn't do all that much, and hence, a further increase to 0.001 may not be all that meaningful.

===== The wife reports on how it feels =======

Coley's Toxins Weeks 1 & 2
Submitted by CancerWife on Sun, 08/22/2010 - 22:37

We had heard and read much about Coley's Toxins and its potential side effects, and now I was to experience it. We want to share my experience with others: how Coley's Toxins actually makes one feel - both immediately during and after treatment. The past two weeks have been like a long experiment. We recorded every sensation I felt during and after the Coley's treatment. Constant temperature, oxygen, pulse and blood pressure measurements gave us more clues on how to ameliorate the side effects.
I am following MBVax's protocol (www.mbvax.com), which calls for intravenous administration and dose escalation to achieve fevers between 102.5-106F. The frequency of administration is five times for the first 6 weeks, then three times a week for 3 weeks, then two times a week for 6 months or more. I am aiming to do Coley's for a total of six months for maximum effectiveness.
During the first two weeks of Coley's Toxins treatment, I have been receiving intravenous infusions on Mon, Wed and Fri.
(unusable pixelated picture of a a [sic ]vial of Coley's Toxins (not MBVAX vial!) - red because of the Serratia marcescens bacteria)

Prewarming
One of the common side effects of Coley's Toxins is chills and shakes. A way to minimize the shakes and chills is to prewarm the patient before the infusion of Coley's Toxins. This raises the body temperature so the body does not need to shake and generate chills to warm the body up as it responds to the Coley's.
Every time before the administration of Coley's, I lie in bed with blankets over me, and a full-body heat pad underneath. I only turn on the heat pad if I don't feel warm enough. After a few times of Coley's, we realized that it is best *not* to sweat before I reach a temperature above 102.5F. Somehow the sweat drains energy from me, making it difficult for me to hit the high temperatures.

Chills
Of the six times that I've had Coley's so far, I have not experienced any shakes. This may be because I am prewarmed, so the body does not need to shake to raise the temperature. I have felt chills though. It feels like a cool breeze along my back. Sometimes it is on one side of my back, going from the top to bottom, or sometimes it goes from left to right, and sometimes it radiates from the center of the back outwards.
Once I feel a chill, I immediately turn on the full-body heat pad. The warmth minimizes the chills. I usually feel 5-10 chills before it stops.
Sometimes during the chills, my bones feel achy.

Fever
Once the chills stop, my temperature starts to climb. During this time, I feel hot and fatigued. Usually the volume of my voice decreases, and I feel like keeping my eyes closed. I try to stay warm but not to a point where I am sweating.
I also keep on sipping electrolytes. MBVax recommends making your own electrolytes with sugar, salt and water, as the store bought ones have too much sugar. The amount of electrolyte I need seems to correlate with how much I've sweat.
I have felt headaches during the fever phase. Usually it's only on one side of the head - a dull headache. It usually goes away by the end of the fever and after I take more oral electrolytes.

Flush phase
It's been quite consistent that when I feel I cannot take the heat anymore and throw away the blankets, that is usually when my temperature starts to decrease. I also feel much warmer and start to sweat more.

After the fever
When my temperature drops to 100-101, I usually feel well enough to eat dinner with a good appetite (see picture below - my dinner after the fever). I don't eat during the fever, so I skip lunch. I am usually a bit fatigued, and my bones feel achy and tired.
The next day I usually feel 100% back to normal. A few times I felt flushed and hot, but that only lasted about 10 mins or so.
An interesting thing is that if I get Coley's on Friday, I feel totally fine on Saturday, but I start to feel a bit fatigued and my bones ache a bit on Sunday.

===== END wife report  =======


== DOSE  0.002ml ==

Coley's Toxins IV #7 - A long but sub-optimal fever   DOSE  0.002ml
Submitted by CancerHusband on Mon, 08/23/2010 - 22:24

Today's fever was uneventful but interesting. We went with an increased dose of 0.002ml thinking that an increase from 0.00075ml to 0.001ml wouldn't do much. We were right.

The chills began 1 hour after infusion start like clockwork. However, 3 hours after infusion start, her temperature was still 101.2F. It became apparent that today's was not going to a very high fever.

The fever stayed mostly between 101 and 102F for a good 3 hours. It briefly touched 102.5F but only for a few minutes.

In general, she was pretty fatigued for the duration of the fever. All other symptoms were consistent with previous fevers - bone pain in the hips, tingling in the fingers, very slight chills (with heating pad), one sided headache, elevated pulse. These were all minor and they all resolved quickly as the fever subsided. However, the fatigue seemed to linger a little longer than usual.

The lingering fatigue might be explained by her anemia. Her Hemoglobin, MCV and MCH were low even before we started on Coley's. The MBVax protocol explains that Coley's may cause anemia itself due to competition in the bone marrow for increased white cell production. Furthermore, it seems that fever itself can lead to a drop in iron levels. Well, today, we got the results of her CBC and Serum Iron test done last Saturday.

    Her iron levels are 33 ug/dL (normal being 50-180).
    Hemoglobin has improved a little to 10.8 (from 10.1)
    MCV declined slightly from 73 -> 72
    MCH declined slightly from 24 -> 23.9
    RDW is high at 18.7

It looks as like this is likely iron deficiency anemia. However, the Issels program does not recommend iron supplementation (iron through food is OK). Nevertheless, we have ordered Floradix iron supplements from the US via mail and hope that it'll make it to the hospital in a couple of days. Strictly speaking, we're not on the Issels treatment plan, but rather, we're following the MBVax protocol. And that protocol does call for Iron supplementation.

I also wonder if this anemia would compromise her body's capability to achieve higher fevers. Regardless, we will try to fix this and hope it'll resolve soon.

On a separate positive note, her total WBC is still at 7500/mm3 (if you remember, it doubled from 4000 to 8000 after the first 3 fevers. It has never been this high, ever, since chemo). In addition, a new development is her lymphocyte count is now at 2000/mm3. This is a first ever since chemo. Her highest has been around 1000/mm3 for the past 2 years since radiation and chemo.

Well, it looks like we'll have to increase dosage again the next time.

== DOSE  0.002ml ==

Coley's Toxins IV #8 - Another sub-optimal fever at 0.002mL
Submitted by CancerHusband on Wed, 08/25/2010 - 23:00

After some deliberation, we decided not to increase the dose level. Instead, we wanted to see if a higher fever could be obtained by increasing external heat instead. After all, we felt that the previous fever (#7) was quite a good one, despite the sub-optimal temperature. It's duration was long and she was quite fatigued after that fever.

Well, as it turns out, increasing the external heat did not lead to a higher fever. Instead, she again developed a fever mainly between 100-101F. This was noticeably lower and of shorter duration than the previous one. She also tolerated it easier and was less fatigued. She did experience some chills but very light ones and very short. She had bone aches from the hip down to the legs.

Our conclusion: increasing external heat did not seem to substantially affect her ability to achieve higher fever. It's clear that we need to escalate dosage.


== DOSE  0.003ml ==

Coley's Toxins IV #9 - A better fever but could be higher. A lingering (but very infrequent) cough.
Submitted by CancerHusband on Sat, 08/28/2010 - 16:37

Today we increased dosage again to 0.003ml. The fever was uneventful and predictable. It was somewhat better than the last one. However, it wasn't as high as we'd hoped for. The peak was a tad below the desired 102.5F threshold. So we'll need to increase again next Monday.

Well, so far, it looks like her Coley fevers are becoming quite predictable and boring -- and that's the way we like it. It'll be interesting though to see if we're able to reach the higher temperatures - and to see how how she tolerates them.

Again, the side effects have been quite minimal. The fatigue, increased heart rate, bone aches that occur during the fever all disappear as the fever subsides. And they are very minor to start with.

The only side effect that seems to somewhat linger on after fevers are gone are a slight cough. It's very infrequent -- we're talking maybe 20 coughs over the entire day.

The doctors think this could be due to general inflammation that Coley's induces. The worse case scenario would be the cough is caused by potential lung tumor(s). Our last scan on June 7th showed two tiny 2mm and 3mm nodules that are suspicious. They were too small to biopsy. Sarcomas can grow very fast. Thus, there's always the possibility that if those were tumors, they may have grown large enough to be symptomatic.

Even so, the cough may not be a bad thing. It could signify the vaccine having positive effect on potential tumors. There's a clear correlation between the frequency & intensity of coughs and the fevers. Coughing is more frequent during fevers - and more so during the fever peak. Regardless, let's hope the cough is due to something else.



===== The wife reports on how it feels =======

Coley's Toxins Week 3
Submitted by CancerWife on Sun, 08/29/2010 - 10:02

This week I had two increases in dosage - to 0.002mL and 0.003mL. Neither dosages gave me sustained fever above 102.5F. Most likely I'm developing some tolerance, so there will be more dose escalation next week.

We learned this week that if I don't sweat much during the fever, I feel more fatigued after the fever ends. This happened on Coley's #7 - I had to rest my head on the dining table during dinner time that night! Thus, for Coley's #8 and #9, we cranked up the heat pad when my fever started to subside. This caused me to sweat more and I had more energy after the fever ended.

Another thing we noticed is my hands have gotten darker. (No, I have not been tanning here in Tijuana :-)) The only other time this happened was during chemotherapy, when I received doxorubicin and ifosfamide. It is a normal side effect of the chemo. It could be that somehow Coley's is causing side effects from chemo to reoccur. Reactivation of "old injuries" has been observed in other patients receiving Coley's.

===== END wife report  =======


== DOSE 0.004ml ==

Coley's Toxins IV #10 - Still not good enough
Submitted by CancerHusband on Mon, 08/30/2010 - 20:43

Today's dosage was again an increase to 0.004ml. This was because last Friday's fever wasn't very high and maxed out at 102.4F for a short duration.

Today's was even lower. It maxed out at 101.9F and for not very long either. I would estimate that the average fever was about 101F. It wasn't very difficult to tolerate and recovery as the fever subsided was very quick.

So it seems clear that her body is developing resistance to the toxins. Let's hope that dose escalation will be able to break this. We will ask the doctors if it would be appropriate to skip the next dose level and go straight to 0.006ml.


== DOSE 0.006ml ==

Coley's Toxins IV #11 - Breaking tolerance
Submitted by CancerHusband on Tue, 08/31/2010 - 21:53

Today, we increased the dosage from 0.004ml -> 0.006ml. We did this because it was becoming apparent that her body is developing tolerance to Coley's Toxins. We felt that increasing to 0.005 wouldn't do too much based on previous fever curves.

Increasing to 0.006ml was probably the right choice. We clearly noticed that today's chills were much more apparent (even with the heat pad). This was more in line with the robust fever from IV#2. Also, the chills occurred about 45min-1 hour after infusion start. This was followed by rise in body temperature shortly after. In contrast, fevers 8, 9 and 10 were slow to happen.

Today's peak was 102.7F. This is above the 102.5F threshold. We were happy about that. However, one interesting thing we noticed is that it dropped off rather quickly (in comparison to robust fever #2).

I wonder what it'll take to re-create a sustained fever. Do we merely need to hit a high enough dose? Or could it be that her body has become more efficient at neutralizing the Toxins? Hmm...


== DOSE 0.009ml ==

Coley's Toxins IV #12 - 104 Fahrenheit
Submitted by CancerHusband on Thu, 09/02/2010 - 17:38

Today, we decided to be a little daring and upped the dosage from 0.006ml -> 0.009ml (a factor of 50%). We decided to do this based on her response from fever #11 where we increased from 0.004->0.006ml. That 50% increase resulted in a clearly better fever, but still not quite high enough.

We got the go ahead from the doctors here. The fever was a little slow to start. Normally, the stronger fevers seemed to manifest chills 1 hour after infusion start. This one was later at almost 2 hours.

The historical records really are true - that robust fevers are clearly associated with more intense chills. Today's chills didn't last that long -- only about 30 minutes. However, it was clear that they were more intense compared to previous ones. Similarly, fever#2 resulted in intense chills as well. Today's chills were continuous and occurred in many places - in her shoulders, arms, legs -- and a new location -- behind her head! I suppose the pillow under her head prevented the heating pad from warming up that area. Nonetheless, it was interesting to that this is the first time chills have occurred there.

Once the chills subsided, her temperature began to rapidly rise. It reached 103.4F about 15 minutes after the chills subsided. Shortly thereafter, it peaked at 104F. This is the first time it's hit that high.

Interestingly, her fever didn't sustain at high levels for long. As in fever#11, it began to drop quite soon after peaking. Nevertheless, it was still a good, robust fever, reaching the highest peak ever.


Other observations:

    The past 2 fevers have not resulted in much aching in her long bones and hips. This occurred quite noticeably in earlier fevers. If those aches were indicative of bone marrow growth, it would be interesting to see how her WBC counts this Saturday are.
    As before, she began coughing 30 mins after infusion of Coley's started. This time, the coughing was more frequent. Not more intense, just more frequent. Her temperature was normal at that time, but her face looked a little flush/red. Later on, during the post-chills phase when her temperature began to rise, I noticed that her cough also became quite frequent. Subsequently, it diminished as her fever decreased.

Note:

    We just spoke with another patient here at the Issels ward. She received Coley's subcutaneously into her arm. She developed a fever of 104F (40C) for 5 hours! Boy, was that a major fever! After the fever broke, she had profuse sweating. The interesting point is that other Issels patients have also reported very long lasting fevers, 8 hours or more in some cases, that had to be stopped with Tylenol. That may be an advantage of subcutaneous administration (the downside being pain at injection site along with possibly unreliable development of fevers due to variable amount of Toxins entering the bloodstream?).


== DOSE 0.009ml ==

Coley's Toxins IV #13 - Revamped fever charts. Figuring out the dry cough.
Submitted by CancerHusband on Sat, 09/04/2010 - 16:31

I've programmed a chart that's hopefully easier for folks to see how the Coley's Toxins fevers progress over time. I did it mainly for ourselves to be able to visualize how a given fever compares with the prior one - and also how it compares with the "best" fever thus far. The best one she's had is fever #2. It was long and protracted, and she stayed well above 102.5F for a good 2.5 hours.

Now, back to today's fever. Since the prior fever was a good one that reached 104F, we chose to stay at the same dose level. That's what the MBVax protocol calls for.

Chills

The chills took a while to develop - but they did come eventually. The chills were frequent but very gentle this time. Mainly a light cool sensation on the back, arms, back of head. Remember now - she has a full body far-infrared heating pad along with blankets and a second chest heating pad. These are turned on and put in place right from the start, before the chills. Again, the purpose is to ward off violent chills and shakes which happen when the body resets it desired temperature point upwards and tries to generate internal heat.

The gentle chills foretold of a lesser fever. Still, she managed to hit 103.1F (39.5C). In all, I estimate that she stayed above 102.2F (39C) for a good 1.5 hours. The plot of this fever (#13) versus the prior one shows a more or less similar curve, except with a lower peak. This indicates her body is beginning to develop tolerance to this dose level (hence the lower peak). We will need to think about whether to increase dosage for next Monday.

Figuring out the cough

For today's infusion, we worked with the doctor here at Issels and decided to eliminate their pre-infusion vitamins and minerals (all prior Coley's infusions were preceded by an IV infusion of B vitamins and minerals to strengthen the body. This was mixed into 500ml saline). For today, all that was given was 250ml of pure saline. The reason we did this was to see if the pre-infusion was contributing to the dry cough that happens each time she gets Coleys.

The doctor also listened carefully to her lungs before infusion, and during the fever, when the cough started up. Here's what we found:

    Her lungs sounded very clear before infusion (when there was no cough)
    During this fever, the cough was noticeably less than the prior fever (#12). Three differences in today's fever are
        Smaller volume of infused liquid (250ml versus 500ml)
        No B vitamins + multi-minerals
        No Coley's dose increase (hence a less intense reaction than #12)
    During the fever cough, the doc listened again very carefully and noted the following:
        When breathing normally, her lungs sound clear -- i.e. no evidence of general bronchial constriction that may be indicative of allergic reaction due to Coleys.
        However, when coughing, it does sound like a "wheeze" (only during the cough).

The doc suggests one possibility is a small tumor that might be pressing on a nerve. Coley's causes tumors to inflame. This might be an explanation for why the cough comes during infusions. The doc didn't think it was a pleural cough. The doc said that a pleural cough would be triggered when one breathes in deeply -- and would manifest in a sharp spasm/pain in the sides. (In her case, she does cough whenever she breathes in deeply, but there are no sharp pains).

Is the dry cough due to general inflammation?

Another possibility that we're pondering is general inflammation caused by Coley's. We've been observing minor but noticeable aches and pains here and there - like on a finger tip, behind the knee cap, in the hip. These generally occur during the peak of the fever.

We can't help but to make an association with an episode 2 years ago when she was given a single shot of Depot Lupron before chemotherapy. This led to all sorts of pains and aches on her chest, ribs, jaw, scalp, shoulder... and it also caused a dry cough. All our doctors and oncologists were totally stumped. CT scan, X-ray, nuclear perfusion tests, blood tests were negative. The ER doc suggested that her cough could be caused by inflammation in the pleura surrounding the lungs. In the end, we did a little experiment, based on the hunch that what we were seeing was generalized systemic inflammation. So she took a single dose of ibuprofen, and that IMMEDIATELY killed the cough and aches and pains. It was like magic - really. Coleys almost definitely causes temporary inflammation. So, you can see why we might believe that the dry cough, aches and pains that we're seeing are due to a generalized inflammatory process.


===== The wife reports on how it feels =======

Post-fever appetite: Coley's #13
Submitted by CancerWife on Sat, 09/04/2010 - 21:32

During my Coley's treatments, I eat breakfast around 8:30am, skip lunch, then I eat dinner after the fever subsides. Today I decided to eat some fruit during the fever, as I was getting quite hungry. I had a plum, then a banana. That wasn't quite enough for me, so after the fever came down, I went down to the cafeteria and asked for a snack. I had two pieces of cake (healthy cake with nuts and fruit) and a cup of apple juice.

Then came dinner time. We went out to a nearby restaurant with other patients. I had a bowl of tortilla soup (with avocado, homemade cheese, tortilla strips) and ostrich steak. The ostrich tastes like very lean beef. I've been low in iron, so I've ordered ostrich a few times already.  I had room even after that! So, I ended the meal with a large piece of carrot cake. After all that eating, I wasn't even stuffed!

I'm in awe that I have very good appetite each time after Coley's. It's such a stark contrast to the time when I had chemo (doxorubicin and ifosfamide). My appetite got worse and worse with each round of chemo, and my weight kept on dropping. With Coley's, I have no problems eating dinner afterwards, and as you can see for today, I can eat quite a large meal!

===== END wife report  =======


== DOSE 0.009ml (+) ==

Coley's Toxins IV #14 - Another good fever.
Submitted by CancerHusband on Mon, 09/06/2010 - 20:08

Today's fever was another good one. She stayed above 102.2F for a good 2 hours.

The fever curve was quite similar to fever #2. The maximum temperature was 103.6F (39.8C). However, you'll notice that it took a little longer to reach its peak. However, once reached, it seemed to stay up there a little longer than recent fevers.

Observations for today's fever:

    Chills lasted for about 20 minutes but were very mild
    The dry cough was even less than fever #13. It occurred only when she would lay on her side. And even so, they were sparse. Could it be that it's resolving??
    She had some numbness and sensitivity in her left hand today -- more so than previous fevers.
    She had a dull headache (mainly center front) and also a transient sharp pain in the back of her head (left side). These are were quite minor (in terms of intensity).

Other than that, I would classify today's a robust fever, with weak chills. Lasted on the longer side at relatively high temperatures.

OK to eat during fever?

The MBVax protocol warns not to eat before Coley's, as well as during the chill phase. I need to check again, but my impression was not to eat during fever as well. It would make sense too, since digestion would probably be impaired during fever.

Well, today we decided to experiment a bit. Whenever she gets Coley's, she doesn't get to eat lunch. And today's Coley's started dripping at around 12:45pm. So, by 4:00pm, she was pretty hungry. Thus, even though she had just reached a high temperature of 103.6F (today's peak), I decided to let her eat a little fruit. We went slow and she had no problems. No nausea. Eventually, she probably ate a full cup of fruit (grapes, canteloupe, papaya). Later on, I gave her a cookie to eat as well.

Interesting observation regarding dilution

Coley's Toxins has to be diluted before being administered intravenously. Today, the Coley's Toxins vial was almost empty. It probably had 0.2ml left, of which 0.1ml was removed, and then diluted. We noticed that it seems a little darker red (more concentrated). This could happen if the vial is not shaken thoroughly each time before extraction. This would result in the remnant solution becoming more and more concentrated. Therefore, even though we kept at 0.009ml, we probably got more than that today.

Possible reactivation of old injuries by Coley's Toxins

We've heard from MBVax that they've observed Coley's reactivating "old injuries". Secondly, the doctors here at Issels believe that Coley's mobilizes toxins and possibly any remnant chemo from the body. They believe it is very important to have a good sweat during/after Coley's (in order to get rid of these toxins).

Well today, we observed something reminiscent of a side effect from chemo 2 years ago. Chemo caused callouses to develop on her fingers, and also some skin peeling. Today, before Coley's started, she observed some of that on her left thumb. She doesn't think it's due to soap because it's only on the left thumb and not on any of the other fingers. A few hours after the fever, she observed little bumps on the thumb. These are all pretty minor, but still noteworthy.


Postponed until tomorrow
Submitted by CancerHusband on Wed, 09/08/2010 - 18:21

Early this morning, she woke up with a slight burning sensation across the upper middle area of her chest. Later on, she felt a slight heavyness in her chest. It would eventually get better by evening time.

The doctors listened carefully to her lungs. They said her lungs sounded clear.

One possibility is she might be fighting off an upper respiratory infection. It's been going around here in the small ward where we are. There are no open windows here so it's hard to get real fresh air.

Our standard protocol when we see the first signs of an upper respiratory infection -- and which has worked very well for us the past 2 years --  is to immediately supplement with the following for no more than 3 days:

    High dose Vitamin D3 - 90,000IU / day for 3 days max
    Sambucol (Black Elderberry extract) - 2-3 Tbsp / day (better than Tamiflu)
    Lactoferrin (between 500mg - 1000mg, twice daily)

Generally, we try to minimize supplements during Coley's. One can do as much research as possible and choose supplements that may be complementary to Coley's. However, there's always a risk of negative interaction. For example, taking high dose fish oil is anti-inflammatory and there is the risk of muting the immune response (which we don't want with Coley's!!). Likewise, there is the theoretical risk for Vitamin D3, Curcumin, and maybe even EGCG. These are all based on our own research trolling through pubmed research articles. Therefore, we intend to take the above supplements only for 3 days maximum.

We'll see how she fares tomorrow. We agree with the doctors that it makes sense to postpone Coley's and re-evaluate come tomorrow.


== DOSE 0.012ml  ==

Coley's Toxins IV #15 - A good fever given the circumstances
Submitted by CancerHusband on Thu, 09/09/2010 - 21:25

This morning, she woke up and felt good enough to to Coley's. There wasn't any "slight burning sensation" in the chest. Neither was there any noticeable heavyness. However, she did have some light yellow phlegm that had to be cleared with some difficulty. So we're thinking that the symptoms she felt yesterday were the beginnings of an upper respiratory infection after all. Perhaps our standard high dose Vitamin D3 - Sambucol - Lactoferrin mix nipped it in the bud, as it has done so reliably for the past 2 years. Only time will tell.

As usual, she received an infusion of saline + B vitamins + multi-minerals. She's received this with almost every Coley fever. This is standard operating procedure at Issels. The actual Coley's was infused beginning at 1pm. It's now 7pm and she's finally gotten up and gone to wash up.

Mild chills

She experienced fleeting chills 1 hour post infusion start. Then, nothing for a while until about 2.5 hours post infusion start. The second occurrence of chills ended up being only about 15 minutes. As usual, they were mild, which we assume is due to our pre-warming with the far infra red pad.

Even milder cough

If you remember, the last Coley's was characterized by a rather mild cough. We were wondering/hoping then that her fever associated cough was beginning to resolve. Well, today's cough was even milder. When coughed only a few times the entire day. There were no spontaneous coughs. They had to be triggered with deep breathing. This happened only after the fever peaked.

Fever strength and duration

The fever peak wasn't very high. But we're not too surprised. We did increase dosage to 0.012ml. We did so because we feel that the previous dosage of 0.009ml was in actuality higher due to the more concentrated remnant fluid left at the bottom of the vial. So, we wanted to stay at the "same dosage" as before. And we took a best guess and estimated it to be 0.012ml, not daring to go higher.

Today's fever peaked at 102.7F. It hovered above the lower threshold of 102.5F for just about an hour and 20 minutes. So, while it wasn't a very high fever, it was a relatively protracted one.

Overall, we were both quite pleased with today's fever given that she was a bit under the weather to start with. An interesting observation:- after the fever, she observed that her lungs felt clearer -- perhaps the fever helped smack down any upper respiratory tract infection! ..... we'll see.....


Back home for the weekend. A four day break.
Submitted by CancerHusband on Sun, 09/12/2010 - 11:32

We're back home for the weekend. She just had a routine Chest CT done and we're waiting for the film lab to burn the disk. As a result of our little haitus, it'll be 4 days break in between Coley's Toxins treatments (we'll resume Coley's next Tuesday).

The MBVax protocol talks about loss of tolerance to Coley's Toxins. Patients who stop Coley's for more than a week are supposed to go back to the beginning and start at 0.001ml all over. Ours will be 4 days - not quite 1 week. We might consider reducing dosage. We'll have to discuss this with the Issels doctors.

Well one thing's for sure, we're enjoying the food back home and eating as much as we can! (The food at Oasis is really quite good, but it's primarily vegetarian)


An unexpected delay in treatment
Submitted by CancerHusband on Tue, 09/14/2010 - 18:56

Sunday night, she suddenly came down with spontaneous shaking chills and high fevers - three of them in the ensuing 24 hours. Her highest registered temperature was 105.6.

After the first fever subsided, we thought it was most likely some viral infection that was resolving. However, when the second one hit, we cancelled the flight back down to San Diego (no way she could walk with the severe chills). We waited for the chills to subside and the fever to spike.

The second fever seemed to resolve after some time. I wanted to take her to the urgent care clinic but she wanted to have a meal. After the meal, the chills hit yet again, and her temperature spiked again.

We took her to the Stanford University ER where they did blood cultures, X-rays, urine samples. They administered broad spectrum IV antibiotics empirically, as there was no obvious infection (no flu like symptoms, no burning during urination, no diarrhea etc).

For many hours the ER doctors had no clear idea what could be causing the fevers. I had to explain to about 6 different physicians our adventures for the past 5 weeks in Mexico.

After about 14 hours, they found evidence of bacterial contamination in her PICC line. They removed the line and sent it for further analysis, hoping to isolate the primary bacterial strain. By that time, she was already beginning to feel much better.

It may take a few days (or more) to take care of this infection. This will cause a delay in her treatment. We won't be going back down to Mexico until this is completely taken care of. Sorry.... but there'll be no Coley's fever graphs until then ....

Delay in Coley's while waiting for Graves' to subside
Submitted by CancerHusband on Sat, 11/27/2010 - 14:23

We're still waiting to resume Coley's. Unfortunately, there's been a resurgence of her Graves' disease (which started in April 2010). One of the symptoms that we have to be careful about is the elevated heart rate due to Graves'. We're trying to get that under control before considering resuming Coley's.

There's the possibility that Coley's caused her Graves' disease to re-surge. However, there are other potential causes including the Pseudomonas sepsis itself, or a recent bad allergic reaction triggered by her PICC dressing.

Our best guess is that she may have had Graves since 2008 (or at least some tendency towards autoimmunity). Why do we think this? Mainly because she experienced a major unexplained bout of systemic inflammation from a single dose of Lupron in 2008, and then half-side body numbness after a single Pneumovax shot in mid 2009. These occurrences were unexplainable and self-limiting. A neurologist-oncologist we consulted with at Stanford concurred with us that the Pneumovax reaction was most likely an autoimmune attack on the nervous system.

There are also historical references to Coley's being used to ameliorate autoimmune diseases such as rheumatoid arthritis. Obviously, we hope that Coley's was not the cause of the Graves' resurgence. Regardless, we will have to proceed carefully in the future to ensure that it does not exacerbate Graves' too much.


END


Chemotherapy drug in combination with Coley's Toxins


A very advanced breast cancer patient (liver and bone metastases) received epirubicin 20mg a week, plus Coleys.
"The results can only be described as amazing"



Epirubicin is an anthracycline drug used for chemotherapy. It is marketed by Pfizer under the trade name Ellence in the US and Pharmorubicin or Epirubicin Ebewe elsewhere.

Similarly to other anthracyclines, epirubicin acts by intercalating DNA strands. Intercalation results in complex formation which inhibits DNA and RNA synthesis. It also triggers DNA cleavage by topoisomerase II, resulting in mechanisms that lead to cell death. Binding to cell membranes and plasma proteins may be involved in the compound's cytotoxic effects. Epirubicin also generates free radicals that cause cell and DNA damage.

Epirubicin is favoured over doxorubicin, the most popular anthracycline, in some chemotherapy regimens as it appears to cause fewer side-effects. Epirubicin has a different spatial orientation of the hydroxyl group at the 4' carbon of the sugar, which may account for its faster elimination and reduced toxicity. Epirubicin is primarily used against breast and ovarian cancer, gastric cancer, lung cancer, and lymphomas.

Development history

The first trial of epirubicin in humans was published in 1980. Upjohn applied for approval by the U.S. Food and Drug Administration (FDA) in node-positive breast cancer in 1984, but was turned down because of lack of data. It appears to have been licensed for use in Europe from around this time however. In 1999 Pharmacia (who had by then merged with Upjohn) received FDA approval for the use of epirubicin as a component of adjuvant therapy in node-positive patients.

Patent protection for epirubicin expired in August 2007.


Monday, July 25, 2011

Afinitor used for Kidney (Renal) Cancer - Old info?

Chemotherapy Drugs Afinitor ($3500 us dollars per 30 day treatmenet

Afinitor is used in the treatment of advanced renal cell cancer, after
sunitinib and sorafenib failure. (sunitinib is one of the most
expensive drugs widely marketed)
.
no wonder they do not want Coley's toxins (Coley's fluid, MBV mixed
bacterial vaccine) to be on the market, because it costs VERY little.
see this video http://www.youtube.com/watch?v=w9wNHw3FCmc extraordinary!!!

Full text

Generic Name: Everolimus

Afinitor is the trade name for the generic name drug everolimus. In
some cases, health care professionals may use the generic name
everolimus when referring to the trade drug name Afinitor.

Drug Type:

Afinitor is a targeted therapy and is classified as an mTOR inhibitor.

What Afinitor Is Used For:

Afinitor is used in the treatment of advanced renal cell cancer, after
sunitinib (see below) and sorafenib failure.

Note: If a drug has been approved for one use, physicians may elect to
use this same drug for other problems if they believe it may be
helpful.

How Afinitor Is Given:

Afinitor is given as a tablet by mouth.
Take at the same time each day, may be taken with or without food.
Swallow whole with a glass of water, do not chew or crush tablets.
Avoid contact with or exposure to crushed or broken tablets.
There are 2 tablet strengths
5mg tablet; white to slightly yellow, elongated tablet with a
bevelled edge and no score, engraved with "5" on one side and "NVR" on
the other
10mg tablet; white to slightly yellow, elongated tablet with a
bevelled edge and no score, engraved with "UHE" on one side and "NVR"
on the other.
The amount of Afinitor that you will receive will be prescribed by
your doctor based on established dosing guidelines.

Afinitor Side effects:

Important things to remember about the side effects of Afinitor:

You will not get all of the Afinitor side effects mentioned below.
Afinitor side effects are often predictable in terms of their
onset, duration, and severity.
Afinitor side effects are almost always reversible and will go
away after therapy is complete.
Afinitor side effects are quite manageable. There are many options
to minimize or prevent them.

The following side effects are common (occurring in greater than 30%)
for patients taking Afinitor:

Low red blood cell count(anemia)
Increased blood cholesterol level
Increased blood trigylceride level
Increased creatinine
Mouth sores
low phosphorus level
Infection
Weakness
Diarrhea
Cough

These are less common (occurring in 10-29%) side effects for patients
receiving everolimus:

Rash
Low blood counts. Your white blood cells and platelets may
temporarily decrease. This can put you at increased risk for
infectionand/or bleeding.
Nausea, vomiting
Increased liver enzymes
Swelling
Poor appetite
Shortness of breath
Fever
Fatigue
Headache
Nosebleeds
Itching
Lung problems
Dry skin

This list includes common and less common side effects for those
taking Afinitor. Side effects that are very rare -- occurring in less
than about 10 percent of patients -- are not listed here. But you
should always inform your health care provider if you experience any
unusual symptoms.

When To Contact Your Doctor or Health Care Provider:

Contact your health care provider immediately, day or night, if you
should experience any of the following symptoms:

Fever of 100.5º F (38º C) or higher, chills (possible signs of infection)

The following symptoms require medical attention, but are not an
emergency. Contact your health care provider within 24 hours of
noticing any of the following:

Nausea (interferes with ability to eat and unrelieved with
prescribed medication)
Vomiting (vomiting more than 4-5 times in a 24 hour period)
Diarrhea (4-6 episodes in a 24-hour period)
Unusual bleeding or bruising
Black or tarry stools, or blood in your stools
Blood in the urine
Pain or burning with urination
Extreme fatigue (unable to carry on self-care activities)
Mouth sores (painful redness, swelling or ulcers)

Always inform your health care provider if you experience any unusual symptoms.

Precautions While Taking Afinitor:

Before starting Afinitor treatment, make sure you tell your doctor
about any other medications you are taking (including prescription,
over-the-counter, vitamins, herbal remedies, etc.).
Do not receive any kind of immunization or vaccination without
your doctor's approval while taking Afinitor.
Inform your health care professional if you are pregnant or may be
pregnant prior to starting this treatment. Pregnancy category D
(Afinitor may be hazardous to the fetus. Women who are pregnant or
become pregnant must be advised of the potential hazard to the fetus.)
For both men and women: Do not conceive a child (get pregnant)
while taking Afinitor. Barrier methods of contraception, such as
condoms, are recommended. Discuss with your doctor when you may safely
become pregnant or conceive a child after therapy.
Do not breast feed while taking this medication.

Self-care Tips While Taking Afinitor:

Drink at least two to three quarts of fluid every 24 hours, unless
you are instructed otherwise.
You may be at risk of infection so try to avoid crowds or people
with colds, and report fever or any other signs of infection
immediately to your health care provider.
Wash your hands often.
To help treat/prevent mouth sores, use a soft toothbrush, and
rinse three times a day with 1 teaspoon of baking soda mixed with 8
ounces of water.
Use an electric razor and a soft toothbrush to minimize bleeding.
Avoid contact sports or activities that could cause injury.
To reduce nausea, take anti-nausea medications as prescribed by
your doctor, and eat small, frequent meals.
Avoid sun exposure. Wear SPF 15 (or higher) sunblock and
protective clothing.
In general, drinking alcoholic beverages should be kept to a
minimum or avoided completely. You should discuss this with your
doctor.
Get plenty of rest.
Maintain good nutrition.
If you experience symptoms or side effects, be sure to discuss
them with your health care team. They can prescribe medications and/or
offer other suggestions that are effective in managing such problems.

Monitoring and Testing While Taking Afinitor:

You will be checked regularly by your doctor while you are taking
Afinitor, to monitor side effects and check your response to therapy.
Periodic blood work will be obtained to monitor your complete blood
count (CBC) as well as the function of other organs (such as your
kidneys and liver) will also be ordered by your doctor.

How Afinitor Works:

Targeted therapy is the result of about 100 years of research
dedicated to understanding the differences between cancer cells and
normal cells. To date, cancer treatment has focused primarily on
killing rapidly dividing cells because one feature of cancer cells is
that they divide rapidly. Unfortunately, some of our normal cells
divide rapidly too, causing multiple side effects.

Targeted therapy is about identifying other features of cancer cells.
Scientists look for specific differences in the cancer cells and the
normal cells. This information is used to create a targeted therapy
to attack the cancer cells without damaging the normal cells, thus
leading to fewer side effects. Each type of targeted therapy works a
little bit differently but all interfere with the ability of the
cancer cell to grow, divide, repair and/or communicate with other
cells.

There are different types of targeted therapies, defined in three
broad categories. Some targeted therapies focus on the internal
components and function of the cancer cell. The targeted therapies
use small molecules that can get into the cell and disrupt the
function of the cells, causing them to die. There are several types
of targeted therapy that focus on the inner parts of the cells.
Other targeted therapies target receptors that are on the outside of
the cell. Antiangiogenesis inhibitors target the blood vessels that
supply oxygen to the cells, ultimately causing the cells to starve.

Researchers agree that targeted therapies are not a replacement for
traditional therapies. They may best be used in combination with
traditional therapies. More research is needed to identify which
cancers may be best treated with targeted therapies and to identify
additional targets for more types of cancer.

Afinitor is an inhibitor of mTOR. mTOR inibition blocks the
translation of genes that regulate cancer cell proliferation. It also
results in reduced levels of certain cell growth factors involved in
the development of new blood vessels, such as vascular endothelial
growth factor (VEGF).

Note: We strongly encourage you to talk with your health care
professional about your specific medical condition and treatments. The
information contained in this website is meant to be helpful and
educational, but is not a substitute for medical advice.


SUNITINIB
is one of the most expensive drugs widely marketed.
Doctors and editorials have criticized the high cost, for a drug that
doesn't cure cancer but only prolongs life.


Sunitinib (marketed as Sutent by Pfizer, and previously known as
SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine
kinase (RTK) inhibitor that was approved by the FDA for the treatment
of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal
stromal tumor (GIST) on January 26, 2006. Sunitinib was the first
cancer drug simultaneously approved for two different indications


Renal cell carcinoma

Sunitinib is approved for treatment of metastatic RCC. Other
therapeutic options in this setting are sorafenib (Nexavar),
temsirolimus (Torisel), interleukin-2 (Proleukin), everolimus
(Affinitor), and bevacizumab (Avastin).

RCC is generally resistant to chemotherapy or radiation. Prior to
RTKs, metastatic disease could only be treated with the cytokines
interferon alpha (IFNα) or Interleukin 2 (IL-2). However, these agents
demonstrated low rates of efficacy (5%-20%).

In a phase 3 study, median progression-free survival was significantly
longer in the sunitinib group (11 months) than in the interferon alfa
group (5 months), hazard ratio 0.42.[6][11] In the secondary
endpoints, 28% of had significant tumor shrinkage with sunitinib
compared to 5% with IFNα. Patients receiving sunitinib had a better
quality of life than IFNα.

At ASCO 2008, Dr Robert Figlin presented updated data from the final
study analysis, including overall survival. The primary endpoint of
median progression-free survival (PFS) remained superior with
sunitinib: 11 months versus 5 months for IFNα, P<.000001. Objective
response rate also remained superior: 39-47% for sunitinib versus
8-12% with IFNα, P<.000001.[12][13]

Sunitinib was associated with somewhat longer overall survival,
although this was not statistically significant.

Median OS was 26 months with sunitinib vs 22 months for IFNα
regardless of stratification (P-value ranges from .051 to .0132,
depending on statistical analysis).
The first analysis includes 25 patients initially randomized to
IFNα who crossed over to sunitinib therapy, which may have confounded
the results; in an exploratory analysis that excluded these patients,
the difference becomes more robust: 26 vs 20 months, P=.0081.
Patients in the study were allowed to receive other therapies once
they had progressed on their study treatment. For a "pure" analysis of
the difference between the two agents, an analysis was done using only
patients who did not receive any post-study treatment. This analysis
demonstrated the greatest advantage for sunitinib: 28 months vs 14
months for IFNα, P=.0033. The number of patients in this analysis was
small and this does not reflect actual clinical practice and is
therefore not meaningful.
Also worth noting in this presentation was the fact that the
updated percentage of patients that had to discontinue sunitinib due
to adverse events was 19%. This is a clinically meaningful number.

This was the largest comparative trial in RCC to date, and sunitinib
is the first agent to demonstrate an overall survival longer than 2
years in these patients.

Hypertension was found to be a biomarker of efficacy in patients with
metastatic renal cell carcinoma treated with sunitinib.[14] Patients
with mRCC and sunitinib-induced hypertension had better outcomes than
those without treatment-induced HTN (objective response rate: 54.8% vs
8.7%; median PFS: 12.5 months, 95% confidence interval [CI] = 10.9 to
13.7 vs 2.5 months, 95% CI = 2.3 to 3.8 months; and OS: 30.9 months,
95% CI = 27.9 to 33.7 vs 7.2 months, 95% CI = 5.6 to 10.7 months; P <
.001 for all).
[edit] Other solid tumors

The efficacy of sunitinib is currently being evaluated in a broad
range of solid tumors, including breast, lung, thyroid and colorectal
cancers. Early studies have shown single-agent efficacy in a number of
different areas. Sunitinib blocks the tyrosine kinase activities of
KIT, PDGFR, VEGFR2 and other tyrosine kinases that are involved in the
development of tumours.

A Phase II study in previously-treated patients with metastatic
breast cancer found that sunitinib "has significant single agent
activity" [15]
A Phase II study of refractory non-small-cell lung cancer found
that "Sunitinib has provocative single-agent activity in previously
treated pts with recurrent and advanced NSCLC, with the level of
activity similar to currently approved agents." [16]
In a Phase II study of patients with nonresectable neuroendocrine
tumors (NET), 91% of patients responded to sunitinib (9% partial
response + 82% stable disease) [17]

Unsuccessful trials

Between April 2009 and May 2011 Pfizer has reported unsuccessful
late-stage trials in breast cancer, metastatic colorectal cancer,
advanced non-small-cell lung cancer, and castration-resistant prostate
cancer.[18]
History

The drug was discovered at SUGEN a biotechnology company which
pioneered protein kinase inhibitors. It was the third in a series of
compounds including SU5416 (Semaxanib) and SU6668. The concept was of
a ATP analogue that would compete with ATP for binding to the
catalytic site of receptor tyrosine kinases.[citation needed] This
concept led to the invention of many small-molecule tyrosine kinase
inhibitors including Gleevec, Sutent, Tarceva and many other cancer
drugs.

Tuesday, July 19, 2011

Liege XGP xgpnFrench text, English google Translation


http://www.urofrance.org/fileadmin/documents/data/PU/2001/PU-2001-00111274/TEXF-PU-2001-00111274.PDF

 Mots-clés : Rein, pyélonéphrite, xanthogranulomateuse, biopsie percutanée, traitement médical.

  O. Reul et coll., Progrès en Urologie (2001), 11, 1274-1276

 CAS CLINIQUE Progrès en Urologie (2001), 11, 1274-1276

  Pyélonéphrite xanthogranulomateuse pseudotumorale : diagnostic
 par la biopsie percutanée et succès du traitement conservateur

 Olivier REUL (1), David WALTREGNY (1), Jacques BOVERIE (2), Jean de LEVAL (1),
 Robert ANDRIANNE (1)

  (1) Service d'Urologie,  (2) Service d'Imagerie Médicale, Centre Hospitalier Universitaire du Sart-Tilman, Liège, Belgique

Manuscrit reçu : avril 2001, accepté : juin 2001.
Adresse pour correspondance : Dr. O. Reul, Service d'Urologie, Université de
Liège, Bloc central, 1, Sart-Tilman, 4000 Liège, Belgique.
e-mail : olivierreul@hotmail.com

 RESUME

 La pyélonéphrite xanthogranulomateuse est une forme
 inhabituelle d'infection rénale dont le diagnostic est
 souvent méconnu avant l'intervention chirurgicale.
 Nous rapportons le cas d'une jeune fille âgée de 19
 ans qui présentait une masse rénale pseudotumorale. Le
 diagnostic de pyélonéphrite xanthogranulomateuse
 focale a été suspecté par les caractéristiques de la
 masse aux différents examens d'imagerie médicale et
 confirmé par l'analyse histologique d'un fragment
 prélevé par une biopsie percutanée échoguidée. La
 guérison a été obtenue avec un traitement
 antibiotique.

 Une exploration exhaustive comprenant une biopsie
 rénale devrait être réalisée afin de poser le
 diagnostic de pyélonéphrite xanthogranulomateuse avant
 tout geste chirurgical. Nous préconisons le traitement
 antibiotique comme traitement de première intention de
 la pyélonéphrite xanthogranulomateuse focale.


 OBSERVATION

Une jeune fille âgée de 19 ans a été adressée à notre
hôpital pour des douleurs lombaires droites
importantes, permanentes, présentes depuis 3 semaines
et en aggravation depuis 3 jours. Lors de son
admission, la patiente était apyrétique et ne signalait
aucun symptôme urinaire. Elle n'avait pas d'antécédents
d'infection urinaire ou de lithiase. L'examen clinique
était sans particularité hormis un point douloureux
costo-musculaire droit.  Il  n'y  avait pas
d'organomégalie ni  de contact lombaire au palper
bimanuel. Sur le plan biologique, il n'y avait pas
d'anomalie à l'exception d'une élévation  de la CRP à
49 mg/l. La leucocytose était de 9780/mm3 dont 64% de
neutrophiles et l'hémoglobine est de 12.3g/dl. La
fonction rénale était conservée avec une urémie de 0.2
g/l et une créatinémie de 8 mg/l. La  culture urinaire
était stérile.

L'échographie rénale a objectivé une masse hétérogène
de 5 cm de diamètre au pôle inférieur du rein droit
tandis que le rein gauche avait un aspect normal. La
tomodensitométrie abdominale a confirmé la présence
d'une lésion de 5 cm à zone centrale hétérogène et
hypodense entourée d'une coque rehaussée par
l'injection de produit de contraste (Figure 1) Une
seconde lésion de 1 x 1,2 cm de mêmes caractéristiques
densitométriques était visible à la partie antérieure
du pôle  inférieur du rein droit. A l'artériographie
rénale sélective, la lésion était hypovascularisée avec
étirement des  vaisseaux  en  périphérie  sans
caractéristique  de vascularisation  anarchique
tumorale  (Figure  4)

L'urographie intraveineuse puis la pyélographie
rétrograde, l'UIV étant insuffisante, ont révélé un
syndrome de masse avec refoulement des tiges
calicielles  inférieures.
 
Nous avons  réalisé  deux biopsies percutanées de  la
lésion  la  plus  volumineuse sous guidage
échographique. L'analyse  anatomo-pathologique  a
révélé un  envahissement  du parenchyme rénal par  un
infiltrat inflammatoire  chronique  formé de
macrophages  d'aspect spumeux associés à des monocytes,
lymphocytes  et  de  la fibrose.  Cet  aspect  était
compatible  avec  le  diagnostic  de pyélonéphrite
xanthogranulomateuse. La culture de la deuxième biopsie
était posi-  tive pour  des  E.  Coli,  sensibles aux
quinolones. La  patiente  a été traitée pendant cinq
semaines par de la ciprofloxacine per  os à raison  de
250 mg  2 fois par j o u r.  Une  réduction
considérable  du  volume  de  la  masse a  été
observée  à  l'examen  tomodensitométrique réalisé
après un mois de traitement (Figure  2)  Trois mois
plus  tard,  la  tomodensitométrie  a révélé
des zones cicatricielles au niveau  des sites des deux
lésions  initiales  (Figure  3). Durant  les  douze  mois
suivants,  aucune  récidive  n 'a ét é const atée.
L'échographie, à un an, était normale

  DISCUSSION

La pyélonéphrite xanthogranulomateuse est une forme de
suppuration rénale chronique survenant à tout âge, le
plus souvent après 40 ans et touchant trois fois plus
fréquemment les femmes que les hommes. La forme focale
est de diagnostic difficile car elle est so confondue
avec  un processus  néoplasique.  L'étiopathogénie de
la pyélonéphrite xanthogranulomateuse n'est pas connue
avec certitude mais plusieurs  facteurs étiologiques
ont été incriminés dont l'obstruction de la voie
excrétrice (lithiase, sténose, tumeur, …), l'infection
urinaire récidivante plus ou moins décapitée  par les
antibiothérapies et les déficits immunitaires [5] Aucun
des ces facteurs n'est présent dans notre observation.

Les patients souffrant de pyélonéphrite
xanthogranulomateuse focale présentent  classiquement
une  douleur intermittente du  flanc,  de  la fièvre,
des frissons ou une altération  de l'état  général avec
perte  de poids. La symptomatologie  dure
habituellement  depuis plusieurs semaines avant que le
diagnostic ne soit posé.

Sur le plan biologique, on note des signes d'infection
avec élévation  des tests inflammatoires (C reactive
protein,  vitesse de sédimentation, fibrinogène) et
hyperleucocytose. La culture urinaire est stérile dans
50 % des cas de pyélonéphrite xanthogranulomateuse
mais la culture du tissu rénal est presque toujours posi-scan.
tive, comme dans notre observation. Les bactéries les
plus souvent en causes sont le Proteus  Mirabilis et  .
l'E.Coli.

La  pyélonéphrite xanthogranulomateuse  focale doit
être  suspectée à  l'examen  tomodensitométrique  qui
révèle classiquement une masse hétérogène centrée sur
une tige calicielle et faiblement rehaussée en
périphérie par le produit de contraste [7]. L'absence
de lymphonoeuds pathologiques, de thrombus veineux ou
de métastases sont des signes importants pour orienter
le diagnostic.  L'échographie rénale,  l'urographie
intraveineuse et la pyélographie rétrograde révèlent un
syndrome de masse aspécifique. Même si la
tomodensitométrie abdominale et l'artériographie ont
permis de suspecter  fortement la nature inflammatoire
et  non  tumorale des lésions rénales dans le cas
présenté, ces deux examens ne peuvent pas exclure
formellement le diagnostic  de lésion néoplasique.
Nous avons  donc opté pour la biopsie percutanée de la
masse rénale, ce ut. Assist. qui a permis de confirmer
le diagnostic de pyélonéphrite xanthogranulomateuse.


Le  traitement  habituel  de  la pyélonéphrite
xanthogranulomat euse focale est malheureusement
souvent la néphrectomie totale ou partielle  [3]. Cette
approche thérapeutique est attribuable à un diagnostic
préopératoire rarement correct ement posé [4]. Le
trait ement  conservateur de la pyélonéphrite
xanthogranulomat euse pseudotumorale par une
antibiothérapie seule est donc une exception, avec de
rares cas  décrits  dans  la  littérature  [1, 2,  6]
Pour ces cas décrits comme  dans le nôtre,  le
traitement  médical  s'est avéré efficace avec une
résolution complète des  lésions rénales. n.

Nous pensons donc qu'une exploration exhaustive suivie
d'une biopsie percutanée pourrait être réalisée afin de
poser le diagnostic de pyélonéphrite
xanthogranulomateuse focale avant tout geste
chirurgical. De plus, la culture des biopsies rénales
permet  d'identifier les micro-organismes en cause et
d'adapter le traitement en fonction de l'antibiogramme.
Nous suggérons l'utilisation du traitement antibiotique
comme traitement de première intention de la
pyélonéphrite xanthogranulomateuse focale à condition
qu il n'y ait pas de pathologie obstructive sousjacente
telle qu'une lithiase ou  une lésion des voies
excrétrices.


  REFERENCES

  1. AIZAWA T., KURATA M., OHKUBO Y. A case of xanthogranulo-
 matous pyelonephritis followed by computed tomographic
 Hinyokika Kiyo, 1998, 44, 729-732.
  2 . BROWN  P.S. Jr,  DODSON  M ., WEINTRUB  P. S
 Xanthogranulomatous pyelonephritis: report of  nonsur-
 gical management of a case and review of the literature. Clin. Infe
 Dis., 1996, 22, 308-314.
 
  3. CHUANG C.K., LAI M.K., CHANG P.L.,HUANG M.H., CHU
 S.H.,  WU C.J.,  WU H.R.  Xanthogranulomatous  pyelonephritis
 experience in 36 cases. J. Urol., 1992, 147, 333-336.
 
 4. EASTHAM J., AHLERING T., SKINNER E. Xanthogranulomatous
  p yelonephritis:  clin ical findings and surgical considerations .
  Urology, 1994, 43, 295-299.
 
  5. MALEK R.S., ELDER J.S. Xanthogranulomatous pyelonephritis: A
 critical analysis of 26 cases and of the literature. J. Urol., 1977
 589-593.
 
 6. MOLLIER S., DESCOTES J.L., PASQUIER D., COQUILLAT P.,
 MICHEL A., DALSOGLIO S., RAMBEAUD J.J. Pseudoneoplastic
 xanthogranulomatous pyelonephritis. A typical clinical presentation
  but unusual diagnosis and treatment. Eur . Urol., 1995, 27, 170-173.
 
 7. SHAH M., HAAGA J.R. Focal xanthogranulomatous pyelonephritis
 simulating a renal tumor: CT characteristics. J. Comp
 Tomogr., 1989, 13, 712-713.
 
  ____________________
 SUMMARY
 
 Pseudo-tumoral xanthogranulomatous pyelonephritis : dia-
 gnosis by percutaneous biopsy and success of conservatory
 treatment.
 Focal xanthogranulomatous pyelonephritis  is an unusual form
 of chronic renal infection that is difficult to diagnose prior to
 surgery. We report on a 19-year-old woman who presented with
 a renal mass that mimicked malignancy. The diagnosis of focal
 xanthogranulomatous  pyelonephritis was  first  suspected  by
 radiological findings and further confirmed by histopathologic
 examination of percutaneous biopsy specimens of the lesio
 Successful treatment of the patient was achieved with antibiotic
 therapy alone. Maximal efforts, including percutaneous rena
 biopsy, should be made to establish the diagnosis of focal xan  -
 thogranulomatous pyelonephritis before a therapeutic decision
 is reached. We recommend the use of antibiotics as a first-line
 treatment for patients with focal xanthogranulomatous pyelone  -
phritis.
 
 Key-words : Kidney, pyelonephritis, xanthogranulomatous, per  -
 cutaneous biopsy, antibiotics.



Figure 2. Après un mois de traitement, diminution importante
de la taille des lésions en tomodensitométrie abdominale


Figure 4. Masse hypovascularisée avec étirement des
vaisseaux en périphérie à l'artériographie rénale sélective.


Figure 3. Aspect cicatriciel au contrôle tomodensitométrique
après 4 mois.



GOOGLE TRANSLATION  ENGLISH

SUMMARY

 Xanthogranulomatous pyelonephritis is a form
 unusual kidney infection whose diagnosis is
 often unrecognized before surgery.
 We report the case of a girl aged 19
 years who had a renal mass pseudotumoral. The
 diagnosis of xanthogranulomatous pyelonephritis
 lens was suspected by the characteristics of the
 mass to different medical imaging and
 confirmed by histological analysis of a fragment
 collected by ultrasound-guided percutaneous biopsy. The
 cure was obtained with treatment
 antibiotic.

 An exhaustive exploration including biopsy
 impairment should be conducted to ask the
 before diagnosis of xanthogranulomatous pyelonephritis
 any surgical procedure. We recommend treatment
 antibiotic as first line treatment of
 Focal xanthogranulomatous pyelonephritis.


 OBSERVATION

A girl aged 19 was sent to our
hospital for back pain right
significant, permanent, present for 3 weeks
and worse for 3 days. During his
admission, the patient was afebrile and reported no
urinary symptoms. She had no history
urinary tract infection or stones. Clinical examination
was unremarkable except for a sore point
costo-muscular right. There was no
of organomegaly or contact palpate lumbar
bimanual. Biologically, there was no
abnormality except for elevation of CRP
49 mg / l. The WBC was 9780/mm3 with 64%
neutrophils and hemoglobin is 12.3g/dl. The
renal function was preserved with a blood urea of ??0.2
g / l and a creatinine of 8 mg / l. Urine culture
was sterile.

Renal ultrasound has objectified a heterogeneous mass
5 cm in diameter at the lower pole of right kidney
while the left kidney had a normal appearance. The
abdominal CT scan confirmed the presence
a lesion of 5 cm central area and heterogeneous
hypodense surrounded by a shell enhanced by
injection of contrast (Figure 1) A
second lesion of 1 x 1.2 cm with the same characteristics
densitometric was visible at the anterior
the lower pole of the right kidney. A arteriography
selective kidney, the lesion was hypovascularisée with
stretching of the vessels in the periphery without
characteristic of chaotic vasculature
tumor (Figure 4)

Intravenous urography and pyelography
retrograde, IVU is insufficient, revealed a
syndrome with mass repression stems
caliceal below.
 
We performed two percutaneous biopsies of
the most voluminous lesion-guided
ultrasound. The pathologic analysis was
revealed invasion of the renal parenchyma by a
chronic inflammatory infiltrate composed of
foamy macrophages aspect associated with monocytes,
lymphocytes and fibrosis. This aspect was
compatible with the diagnosis of pyelonephritis
xanthogranulomatous. The culture of the second biopsy
was posi-tive for E. Coli sensitive to
quinolones. The patient was treated for five
weeks of ciprofloxacin orally at a rate of
250 mg two times a j o u r. A reduction
in the volume of the mass was
observed in the CT scan performed
After one month of treatment (Figure 2) Three months
later, CT revealed
scarred areas at the sites of two
initial lesions (Figure 3). During the twelve months
following no recurrence n 'a and e const ATEE.
The ultrasound at one year, was normal

  DISCUSSION

Xanthogranulomatous pyelonephritis is a form of
chronic renal suppuration occur at any age,
usually after 40 years and three times more
common in women than men. Form focal
is difficult to diagnose because it is so confused
with a neoplastic process. The etiopathogenesis of
Xanthogranulomatous pyelonephritis is not known
with certainty, but several causal factors
which have been implicated tract obstruction
excretory (stones, stricture, tumor, ...), infection
recurrent urinary tract more or less decapitated by
antibiotics and immune disorders [5] No
of these factors is present in our observation.

Patients with pyelonephritis
Focal xanthogranulomatous conventionally
intermittent flank pain, fever,
chills or impairment of general health with
weight loss. The symptoms lasted
usually for several weeks before the
diagnosis is made.

Biologically, there are signs of infection
Elevated inflammatory tests (C reactive
protein, sedimentation rate, fibrinogen) and
leukocytosis. The urine culture is sterile
50% of cases of xanthogranulomatous pyelonephritis
but the culture of kidney tissue is almost always positive scan.
tive, as in our observation. The bacteria
most frequently involved are Proteus Mirabilis and.
E. Coli.

Focal xanthogranulomatous pyelonephritis should
be suspected that the CT scan
typically shows a heterogeneous mass centered
stem and calyx slightly enhanced by
periphery by the contrast [7]. The absence
lymphonoeuds of pathological thrombus or venous
metastases are important signs to guide
diagnosis. Renal ultrasound, urography
Intravenous pyelography and retrograde reveal a
Mass nonspecific syndrome. Although
abdominal CT scan and arteriography have
allowed to suspect strongly inflammatory
and non-tumor kidney damage in the case
presented, these two tests can not exclude
formal diagnosis of neoplastic lesions.
So we opted for percutaneous biopsy of
renal mass, it ut. Assist. which confirmed
the diagnosis of xanthogranulomatous pyelonephritis.


The usual treatment of pyelonephritis
Focal xanthogranulomatous euse is unfortunately
often the total or partial nephrectomy [3]. This
therapeutic approach is due to a diagnosis
Correct preoperative rarely posed no way [4]. The
Conservative in no way related pyelonephritis
Xanthogranulomatous euse pseudotumoral by
antibiotic therapy alone is an exception, with
rare cases described in the literature [1, 2, 6]
For these cases described as in ours,
Medical treatment was effective with
complete resolution of renal injury. n.

We therefore followed an exhaustive exploration
a percutaneous biopsy may be performed to
the diagnosis of pyelonephritis
Focal xanthogranulomatous before any action
surgery. In addition, the culture of renal biopsies
to identify the microorganisms involved and
to adapt the treatment according to the antibiogram.
We suggest the use of antibiotics
as first-line treatment of
Focal xanthogranulomatous pyelonephritis provided
that there is no patho-logy obstructive sub-
predicate such as stones or injury tract
excretory.

GOOGLE TRANSLATION TO GERMAN


ZUSAMMENFASSUNG

 Xanthogranulomatöse Pyelonephritis ist eine Form
 ungewöhnliche Nierenentzündung, deren Diagnose
 oft unerkannt vor der Operation.
 Wir berichten über den Fall eines Mädchens im Alter von 19
 Jahren, die eine renale Masse pseudotumoral hatte. Die
 Diagnose xanthogranulomatöse Pyelonephritis
 Objektiv wurde von den Eigenschaften der Verdacht
 Masse zu verschiedenen Bereichen medizinische Bildgebung und
 bestätigt durch histologische Analyse eines Fragments
 gesammelt durch Ultraschall-gesteuerte perkutane Biopsie. Die
 Heilung wurde mit der Behandlung erhalten
 Antibiotikum.

 Eine erschöpfende Untersuchung einschließlich Biopsie
 Beeinträchtigungen sollten durchgeführt, um die fragen
 vor der Diagnose des xanthogranulomatöse Pyelonephritis
 jedem chirurgischen Eingriff. Wir empfehlen die Behandlung
 Antibiotika als First-Line Behandlung von
 Focal xanthogranulomatöse Pyelonephritis.


 BEOBACHTUNG

Ein Mädchen im Alter von 19 wurde gesendet
Krankenhaus für Rückenschmerzen rechts
signifikante, dauerhafte Geschenk für 3 Wochen
und schlimmer noch für 3 Tage. Während seiner
Aufnahme war der Patient fieberfrei und berichteten keine
Beschwerden beim Wasserlassen. Sie hatte keine Geschichte
Harnwegsinfektion oder Steine. Die klinische Untersuchung
war bis auf einen wunden Punkt unauffällig
costo-muskulösen rechten Seite. Es gab keine
von Organomegalie oder kontaktieren Sie tasten Lendenwirbelsäule
bimanuelle. Biologisch, gab es keine
Anomalie mit Ausnahme Höhe von CRP
49 mg / l. Der WBC war 9780/mm3 mit 64%
Neutrophilen und Hämoglobin 12.3g/dl. Die
Nierenfunktion wurde mit einem Blut-Harnstoff von 0,2 erhalten
g / l und einem Kreatinin von 8 mg / l. Urinkultur
war steril.

Renal Ultraschall hat eine heterogene Masse objektiviert
5 cm im Durchmesser am unteren Pol der rechten Niere
während die linke Niere hatte eine normale Erscheinung. Die
Bauch-CT bestätigte die Anwesenheit
eine Läsion von 5 cm zentralen Bereich und heterogenen
hypodense von einer Hülle umgeben, verstärkt durch
Injektion von Kontrastmittel (Abbildung 1) A
zweite Läsion von 1 x 1,2 cm mit den gleichen Eigenschaften
densitometrische wurde an der vorderen sichtbaren
den unteren Pol der rechten Niere. Eine Arteriographie
selektive Niere, wurde die Läsion hypovascularisée mit
Dehnung der Gefäße in der Peripherie ohne
Merkmal der chaotischen Gefäßsystem
Tumor (Abbildung 4)

Intravenöse Urographie und Pyelographie
retrograde, IVU ist unzureichend, ergab eine
Syndrom mit Masse Repression beruht
caliceal unten.
 
Wir führten zwei perkutanen Biopsien
die umfangreichste Läsion-guided
Ultraschall. Die pathologische Analyse wurde
zeigte Invasion des Nierenparenchyms durch eine
chronisch-entzündliche des Infiltrat
schaumigen Makrophagen Aspekt mit Monozyten assoziiert,
Lymphozyten und Fibrose. Dieser Aspekt wurde
kompatibel mit der Diagnose Pyelonephritis
xanthogranulomatöse. Die Kultur der zweiten Biopsie
war positiv für E. Coli sensibel auf
Chinolone. Der Patient wurde für fünf behandelt
Wochen Ciprofloxacin oral mit einer Geschwindigkeit von
250 mg zweimal j o u r. Eine Reduktion
in das Volumen der Masse
beobachtet in den CT-Scan durchgeführt
Nach einem Monat der Behandlung (Abbildung 2) Drei Monate
später enthüllte CT
vernarbten Bereiche an den Standorten von zwei
ersten Läsionen (Abbildung 3). Während der 12 Monate
folgenden kein Rezidiv n 'a und e const ATEE.
Der Ultraschall nach einem Jahr wurde der Normalwert

  DISKUSSION

Xanthogranulomatöse Pyelonephritis ist eine Form der
chronischer Niereninsuffizienz Eiterung in jedem Alter,
in der Regel nach 40 Jahren und drei Mal mehr
bei Frauen häufiger als Männer. Form Mittelpunkt
ist schwer zu diagnostizieren, weil sie so verwirrt ist
mit einer neoplastischen Prozess. Die Ätiopathogenese der
Xanthogranulomatöse Pyelonephritis ist nicht bekannt,
mit Sicherheit, aber mehrere ursächliche Faktoren
die wurden Obstruktion verwickelt
Ausscheidungsorgane (Steine, Strikturen, Tumor, ...), Infektion
rezidivierenden Harnwegsinfektionen mehr oder weniger geköpft durch
Antibiotika und Immunstörungen [5] Keine
dieser Faktoren ist in unserer Beobachtung.

Patienten mit Pyelonephritis
Focal xanthogranulomatöse konventionell
intermittierende Flankenschmerzen, Fieber,
Schüttelfrost oder Beeinträchtigung der allgemeinen Gesundheit mit
Gewichtsverlust. Die Symptome dauerten
in der Regel mehrere Wochen vor dem
Diagnose gestellt wird.

Biologisch gibt es Anzeichen einer Infektion
Erhöhte entzündliche Tests (C-reaktives
Protein, Blutsenkungsgeschwindigkeit, Fibrinogen) und
Leukozytose. Der Urin ist steril Kultur
50% der Fälle von xanthogranulomatöse Pyelonephritis
aber die Kultur des Nierengewebes ist fast immer positiv zu scannen.
TIVE, wie in unserer Beobachtung. Die Bakterien
Am häufigsten betroffen sind Proteus mirabilis und.
E. Coli.

Focal xanthogranulomatöse Pyelonephritis sollte
werden vermutet, dass die CT-Scan
zeigt typischerweise eine heterogene Masse zentrierte
Stamm und Kelch leicht durch verstärkte
Peripherie durch den Kontrast [7]. Das Fehlen
lymphonoeuds von pathologischen Thrombus oder venösen
Metastasen sind wichtige Zeichen zu führen
Diagnose. Renal Ultraschall, Urographie
Intravenöse Pyelographie und retrograde zeigen eine
Messe unspezifischen Syndrom. Obwohl
Bauch-CT und Angiographie haben
darf vermuten, stark entzündliche
und Nicht-Tumor Nierenschäden bei
präsentiert, können diese beiden Tests nicht ausschließen,
formale Diagnose neoplastischer Läsionen.
So entschieden wir uns für eine perkutane Biopsie
Nieren-Masse, es ut. Assist. die bestätigt
die Diagnose von xanthogranulomatöse Pyelonephritis.


Die übliche Behandlung der Pyelonephritis
Focal xanthogranulomatöse euse ist leider
oft die vollständige oder partielle Nephrektomie [3]. Dieser
therapeutische Ansatz beruht auf einer Diagnose
Korrekte präoperative selten gestellt keiner Weise [4]. Die
Konservative in keiner Weise im Zusammenhang Pyelonephritis
Xanthogranulomatöse euse pseudotumoral durch
Antibiotika-Therapie allein ist eine Ausnahme, mit
seltenen Fällen in der Literatur [1, 2, 6] beschrieben
Für diese Fälle als in unseren beschrieben,
Ärztliche Behandlung wirksam war mit
eine vollständige Rückbildung der Nierenschädigung. n.

Deshalb folgte eine erschöpfende Untersuchung
eine perkutane Biopsie kann durchgeführt werden
die Diagnose der Pyelonephritis
Focal xanthogranulomatöse vor jeglicher Aktion
Chirurgie. Darüber hinaus die Kultur des Nierenbiopsien
zur Identifizierung der Mikroorganismen beteiligt und
die Behandlung nach dem Antibiogramm anzupassen.
Wir empfehlen den Einsatz von Antibiotika
als First-Line-Behandlung von
Focal xanthogranulomatöse Pyelonephritis vorgesehen
dass es keine patho-logie obstruktive sub-
Prädikat wie Steine ??oder Verletzungen Darm-Trakt
Ausscheidungsorgane.

Monday, July 18, 2011

Vaccineurin also a GDR Product

As it turns out, the East Germans (DDR) made Vaccineurin, too.  It seems to have been used for psychiatry as well.
When Suedmedica in Munich stopped production of coley's toxins-type vaccineurin, the sächsiche serumwerke did too.
Maybe both were taken over by Glaxo smith kline?

Much good research on vaccines must have been undertaken in Dresden.  Below is a german story,
and a google translation in english

In Dresden 1911 much money was spent on a ferment-technique to identify cancer. Who knows what that was?
Please leave a comment!!


http://www.dhm.de/gos-cgi-bin/jpeglogoneu?ak601/ak601286

Verpackung des Vaccineurin II-Serums mit Gebrauchsanweisung

Datensatz GOS-Nr.  AK601285
Inventarnr.  HI 72/132.22
Alltagskultur I: Gesundheitswesen > Medizin > Impfstoff > Vaccineurin B

Verpackung des Vaccineurin B-Serums

Datierung: von 1961 bis 1969
Werkstatt: Sächsisches Serumwerk KG, Dresden
Entstehungsort: Dresden
Entstehungsland: Deutschland
[historisch: Deutsche Demokratische Republik]
________________________________
Maße: 1,5 cm (Höhe), 7 cm (Breite), 8,6 cm (Länge)
Material/Technik:  Papier : Pappe / gestanzt, gepresst
________________________________
Schlagworte: Arzneimittel · Verpackung · Gesundheitswesen · Medizin · DDR-Produkt ·

http://www.dhm.de/gos-cgi-bin/jpeglogoneu?ak601/ak601282

Vaccineurin I


http://www.dhm.de/gos-cgi-bin/jpeglogoneu?ak601/ak601283

Vaccineurin 1/15

http://www.dhm.de/gos-cgi-bin/jpeglogoneu?ak601/ak601285
Vaccineurin B


http://www.dhm.de/gos-cgi-bin/jpeglogoneu?ak601/ak601284

Febrivaccin Serie II zur Fiebertherapie von 1961 bis 1969

2008  Das Sächsische Serumwerk Dresden bekommt einen neuen Namen: GlaxoSmithKline Biologicals
1991  Übernahme vom SSW durch SmithKline Beecham   Zirkusstraße 40, D- 01069 Dresden
In den Jahren 1909 bis 1910 erfolgte der Aufbau des Sächsischen Serumwerkes und Institutes für Bakteriotherapie auf der Löbtauer Str.45
Die dabei erzielten Gewinne ermöglichten die kostspieligen Untersuchungen zur Herstellung eines
Karzinomserums für die fermentative Erkennung von Krebserkrankungen.
Für diesen Zweck inve- stierte das Serumwerk etwa 100.000 Goldmark.

http://u.jimdo.com/www25/o/se6e58aea4731bd32/img/i071af5ecb6c12486/1279796545/std/image.jpg


Sächsisches Serumwerk Dresden um 1915

http://lingner-archiv.jimdo.com/lingner-biographie/s%C3%A4chs-serumwerk/

Sächsisches Serumwerk

Es waren vor allem der Botaniker und Pflanzenphysiologe Ferdinand Julius Cohn (1828-1898) und Robert Koch (1843-1910), die die wissenschaftliche Bakteriologie in Deutschland begründeten. Beschäftigte sich die bakteriologische Forschung in ihrer frühen Entwicklungsphase insbesondere mit den Möglichkeiten des Erregernachweises, so wuchs in den achtziger Jahren des 19. Jahrhunderts das Interesse an spezifischen Bakteriengiften und vom Körper gebildeten Antitoxinen. 1890 konnte der Koch-Schüler und -Mitarbeiter Emil von Behring (1854-1917) durch Immunisierungs- versuche an Tieren die Bildung von Antitoxinen belegen. Es gelang ihm in den neunziger Jahren, ein Diphtherieserum (ein Antitoxinkonzentrat gegen Diphtheriebakterien) zu entwickeln und erstmalig diphtheriekranke Kinder erfolgreich zu behandeln. Damit war der Anfang der serumtherapeutischen Ära gemacht, und es entwickelte sich in der Folgezeit die Blutserumtherapie. Lingner war von der Möglichkeit, Bakterien mit ihren "eigenen Waffen" zu bezwingen, begeistert und plante schon frühzeitig die Herstellung von entsprechenden Substanzen. Hueppe berichtete, dass die Einführung des Diphtherieserums durch von Behring (dieser hatte dafür 1901 den Nobelpreis erhalten) Lingner zur Aufnahme der Se- rumherstellung veranlasste. 1902 erwarb Lingner von dem bekannten Münchner Bakteriologen Prof. Rudolph Emmerich (geb. 1852) das Verfahren zur Herstellung von Pyocyanase. Dieses von Pyocyaneus-Kulturen gebildete bakteriolytische Enzym fand als Heilmittel gegen Diphtherie, Blutvergiftung, Milzbrand, Soor und Genickstarre Verwendung.

1903 begründete Lingner im Dresdner Chemischen Laboratorium Lingner die Bakteriologische Abteilung zur Herstellung von Pyocyanase. Diese Abteilung auf der Nossener Str.2/4 wurde von Dr. L. Lange geleitet. Hier erfolgte auch die Fertigung von Modellen, Moulagen und Bakterienkulturen für die Ausstellung "Volkskrankheiten und ihre Bekämpfung" 1903 in Dresden. Somit war auch der Vorläufer der späteren Lehrmittelwerkstätten des Deutschen Hygiene-Museums begründet. 1904 wurde die Bakteriologische Abteilung nach der Kaitzer Straße 22, I. Etage, verlegt und in Folge als Bakteriologisches Institut bezeichnet. Das Institut besaß unter anderem technische Einrichtungen zur Herstellung von Pyocyanase. In Kulturkolben erfolgte die Anzüchtung von Pyocyaneus-Kulturen, die das bakteriolytische Enzym bilden. Durch Filtration und Eindampfung im Vakuum wurde die Enzymlösung auf 1/10 ihres Volumens konzentriert. Mittels eines Elektromotors erfolgte die Herstellung der dazu erforderlichen luftleeren Flaschen. Im Juni 1906 verließ Dr. Lange das Institut und erhielt 1907 eine Privat-Dozentur an der Kgl. Sächs. Technischen Hochschule in Dresden. Um 1912 wurde Prof. Lange als Oberregierungsrat an das Reichs- gesundheitsamt Berlin berufen. Nach dem Ausscheiden von Lange über- nahm der Apotheker Glaser, ehemaliger Mitarbeiter von Prof. Emmerich, die Leitung des Bakteriologischen Institutes. Neben Glaser waren zwei Che- miker und zwei Diener im Institut beschäftigt. Inwieweit die Pyocyanase als pharmazeutisches Produkt verkauft bzw. in der Kinderklinik mit Säuglingsheim zur Anwendung gelangte, konnte nicht ermittelt werden. Auch fehlen Belege über eine mögliche Zusammenarbeit zwischen dem Bakteriologischen Institut und der Zentralstelle für Zahnhygiene. Letztere Ein- richtung befand sich von 1904-1906 im Erdgeschoss der Kaitzer Straße 22. Carl Roese, ihr Leiter, war vor seiner Berufung nach Dresden ebenfalls bei Prof. Emmerich in München bakteriologisch tätig. Das Bakteriologische Institut wurde 1908 in die erweiterte Fabrik auf der Nossener Str.2/4 verlegt. Für die weitere Entwicklung des Bakteriologischen Institutes bis zur Gründung des Sächsischen Serumwerkes waren die sich entwickelnden Kontakte zum Hygiene Institut der Universität Bern und dem Schweizer Serum- und Impfinstitut Bern entscheidend. Über das Zustandekommen dieser Beziehung lassen sich folgende Vermutungen anstellen: Zur Vorbereitung der Ausstellung "Volkskrankheiten und ihre Bekämpfung" 1903 begründete Lingner ein Ehrenkomitee, in dem unter anderem Prof. Richard Pfeiffer (1858- 1945), der Entdecker des Influenza-Bazillus und Bakteriolysins von Choleravibrionen, mitarbeitete. Über Pfeiffer könnte Lange, der wissenschaft- liche Betreuer der Ausstellung und Leiter der Bakteriologischen Abteilung, Verbindung zum Direktor des Hygiene Institutes der Universität Bern, Prof. Wilhelm Kolle (1868-1935), aufgenommen haben. Professor Pfeiffer arbeitete jahrelang mit Professor Kolle über Grundlagen der Immunität bei Cholera- und Typhusinfektionen zusammen. Auch ein unvermittelter Besuch Lingners am Hygiene Institut der Universität Bern scheint denkbar, da er in Vorbereitung seiner Ausstellung 1903 mehrere Universitätsinstitute besuchte, um sich insbesondere Sammlungen von Bakterienreinkulturen anzusehen.

Prof. Kolle fungierte als Wissenschaftlicher Leiter des 1898 in Bern gegründeten Schweizer Serum- und Impfinstitutes. Ein Protokoll der Aufsichtsratssitzung des Schweizer Serum- und Impfinstitutes vom 9. Januar 1909 beleuchtet die Zusammenarbeit mit Lingner [158]. Demnach vermittelte Prof. Kolle die Kontakte zwischen Lingner und dem Schweizer In- stitut. Auf Betreiben Kolles wurden seit Oktober 1908 Vgeführt, die im Januar 1909 zum Abschluss kamen. Danach verpflichtete sich das Schweizer Serum- und Impfinstitut zur Unterstützung beim Aufbau des Sächsischen Serumwerkes und zur Überlassung von Absatzmärkten. Als Leiter des zu gründenden Sächsischen Serumwerkes wurde Privatdozent Dr. Otto Heller eingesetzt. Heller habilitierte sich als Privatdozent und war am Berner Universitäts-Institut für Infektionskrankheiten unter Kolle tätig. Zu seinen Forschungsthemen zählte der Versuch zur Herstellung eines nichtinfektiösen Impfstoffes gegen Tollwut [193]. Prof. Kolle versicherte gegenüber dem Schweizer Serumwerk, die wissenschaftliche Oberleitung in Dresden für mindestens drei Jahre zu führen. Lingner verpflichtete sich zur Zahlung von jährlich zehn Prozent des Reingewinns (Minimum: 8.000 Mark) für zehn Jahre an das Schweizer Serumwerk. Zusätzlich hatte Lingner eine Pauschalabfindung von 50.000 Mark zu zahlen. Davon erhielt Kolle zweimal 6.000 Mark und vom Reingewinnanteil 3.000 Mark pro Tätigkeitsjahr.

Nach Vertragsabschluß wurde Lingner Aufsichtsratsmitglied im Schweizer Serum- und Impfinstitut Bern. Er gewährte dem Schweizer Institut eine Anleihe von 5.000 Franken, Zeitpunkt und Grund sind unbekannt [41]. Im Februar 1909 teilte Lingner dem Ministerium des Innern mit, dass er beabsichtigt, auf der Löbtauer Straße 45 "Einrichtungen für die Fabrikation und den Vertrieb von Heilsera zu treffen". Zu diesem Zwecke mietete er von der Aktienbierbrauerei Gambrinus entsprechende Gebäude. Unter Hellers Leitung entstanden Räume für die Verwaltung, Laboratorien, Ställe für 30 Pferde zur Serumgewinnung und Kühl-, Aufbewahrungs-, Ab- füll- und Verpackungsräume.

In den Jahren 1909 bis 1910 erfolgte der Aufbau des Sächsischen Serumwerkes und Institutes für Bakteriotherapie auf der Löbtauer Str.45. Daneben bemühte sich Lingner, die formellen Genehmigungen für die geplante Serumherstellung zu beschaffen. Neben dem Innenministerium, der Kreishauptmannschaft Dresden und der Medizinalpolizei mußte das Gewerbeamt tätig werden.

1910 zeigte Lingner dem Gewerbeamt Dresden die Absicht zur Eröff- nung des Sächsischen Serumwerkes und Institutes für Bakteriotherapie an. Mit Schreiben des Gewebeamtes vom 19.Juli 1910 erhält Lingner letztendlich die Erlaubnis "...zur Herstellung und Vertrieb der Heilseris". Am 17. Oktober 1911 wurde das Sächsische Serumwerk und Institut für Bakterio- therapie als GmbH im Handelsregister beim Amtsgericht Dresden registriert. Das Direktorat wurde mit Otto Heller besetzt und die Herren Bethke und Reichelt zu Geschäftsführern ernannt, auch war Georg Seiring an der Leitung des Unternehmens beteiligt. Lingner hielt als Vorsitzenderer des Aufsichtsrates maßgebliche Gesellschaftsanteile. Erste Erfolge erzielte das Sächsische Serumwerk mit der umfassenden Bereitstellung von Seren und Impfstoffen gegen Cholera und Typhus im ersten Balkan- krieg 1912/13. Die dabei erzielten Gewinne ermöglichten die kost- spieligen Untersuchungen zur Herstellung eines Karzinomserums für die fermentative Erkennung von Krebserkrankungen. Für diesen Zweck inve- stierte das Serumwerk etwa 100.000 Goldmark. Ab 1912 führte eine bakte- riologisch-serologische Untersuchungsstelle im Serumwerk unter anderem die Wassermann ́sche Reaktion zur Syphilisdiagnostik durch.

Der erste Weltkrieg setzte diesen intensiven Forschungen jedoch vor- erst ein Ende, da an der Front ein großer Bedarf an Tetanusserum zu decken war. Auch wurden Seren gegen Diphtherie, Ruhr, Cholera, Gasbrand und Strepto- und Pneumokokken sowie Pest benötigt und hergestellt. Seiring beschreibt die Situation wie folgt: "Der Krieg brachte aber wieder andere Aufgaben. Man hatte allgemein mit einer kurzen Kriegsdauer gerechnet und deshalb für eine längere Zeit nicht vorgesorgt. Das Sanitätswesen war am meisten im Rückstand. So fehlte u.a. Tetanus-Serum fast vollständig. Ich übernahm die betriebliche Leitung des Sächsischen Serumwerkes und ließ sofort 200 Pferde impfen, die wir von der Heeresleitung zur Verfügung gestellt bekamen, um tunlichst schnell das wichtige Serum zu beschaffen. Zusätzlich zur eigenen Produktion erwarb das Sächsische Serumwerk im Auftrag der deutschen Heeresverwaltung Seren im Ausland, dabei könnte Lingner seine Beziehungen zum Schweizer Serum- und Impfinstitut genutzt haben. Nach dem ersten Weltkrieg arbeitete das Sächsische Serumwerk vorrangig auf dem Gebiet

der Syphilisbekämpfung, der Proteinkörper-Therapie und der Tu- berkulosebekämpfung. Nach Lingners Tod wurde entsprechend der testamentarischen Verfügung den Angestellten und Arbeitern des Sächsischen Serumwerkes eine einmalige Geldzuwendung in der Gesamthöhe von etwa 6.700 Mark ausgezahlt. Lingners Gesellschaftsanteile konnten im Fe- bruar 1917 mit einem Gewinn von 30.000 Mark verkauft werden. Nach der Umwandlung zur Aktiengesellschaft 1922 wurde im Sinne Lingners ein Vertreter der Landesregierung Sachsens in den Aufsichtsrat delegiert, um die Interessen der Allgemeinheit für die Bekämpfung der Volkskrankheiten zu sichern. Die Beziehungen zum Schweizer Serum- und Impfinstitut blieben durch die Berufung seines Direktors, Paul Gardinaux, in den Aufsichtsrat des Sächsischen Serumwerkes bestehen.

google translation


Saxon Serum Plant

It was primarily a botanist and plant physiologist Ferdinand Julius Cohn (1828-1898) and Robert Koch (1843-1910) who founded the scientific bacteriology in Germany. Employees in the bacteriological research in its early development stage, particularly with the possibilities of pathogen detection, it grew in the eighties of the 19th Century, interest in specific bacterial toxins and antitoxins made by the body. 1890, the cooking school staff and Emil von Behring (1854-1917) supported by immunization experiments in animals, the formation of antitoxins. He succeeded in the nineties to develop a diphtheria serum (an anti-toxin concentrate against diphtheria bacteria) and to treat children suffering from diphtheria for the first time successfully. Thus the beginning of the therapeutic serum era was made, and it developed in the period following the serum therapy. Lingner was the possibility of bacteria with their own "weapons" to defeat, thrilled and planned early on the production of corresponding substances. Hueppe reported that the introduction of the diphtheria serum from Behring (this had it received the 1901 Nobel Prize) Lingner to accommodate the production of serum induced. Lingner 1902 acquired by the famous Munich bacteriologist Professor Rudolph Emmerich (born 1852), the process for the production of pyocyanase. This formed by pyocyaneus cultures bacteriolytic enzyme found as a remedy for diphtheria, blood poisoning, anthrax, thrush and use a stiff neck.

Founded in 1903 Lingner Lingner Dresdner chemical laboratory for the production of the Bacteriological Department pyocyanase. This department on the Nossener Str.2 / 4 was directed by Dr. L. Lange. This was also the production of models, plaster casts, and bacteria cultures for the exhibition "common diseases and their control" in 1903 in Dresden. Consequently, the precursor of the later teaching aid workshops of the German Hygiene Museum was founded. In 1904, the Bacteriological Department after 22 Kaitzer street, I. floor was laid, and named in sequence as the Bacteriological Institute. The Institute had among other technical equipment for the manufacture of pyocyanase. In culture flasks was the cultivation of pyocyaneus cultures that make up the bacteriolytic enzyme. By filtration and evaporation in vacuum, the enzyme solution to 1 / 10 of their volume was concentrated. By an electric motor was required to manufacture the vacuum bottles. In June 1906, Dr. Long left the institute in 1907 and received a private teacher at the Kgl. Saxon. Technische Hochschule in Dresden. By 1912 Professor Lange was appointed as a senior executive officer of the Reich Health Office in Berlin. Following the departure of Long took over the pharmacist Glaser, former co-worker of Prof. Emmerich, head of the Bacteriological Institute. Glaser next two chemists and two servants were employed at the Institute. The extent to which pyocyanase as a pharmaceutical product sold in the children's hospital or home for use with infants arrived, could not be determined. Also, evidence is lacking on possible cooperation between the Bacteriological Institute and the Centre for dental hygiene. The latter facility was located on the ground floor of 1904-1906 Kaitzer 22nd Street Carl Roese, its director was, before his appointment to Dresden with Prof. Emmerich also bacteriologically active in Munich. The Bacteriological Institute was expanded in 1908 moved the factory to the Nossener Str.2 / 4. For the further development of the Bacteriological Institute until the founding of the Saxon Serumwerk the developing contacts with the Hygiene Institute of the University of Bern and the Swiss Serum and Vaccine Institute Berne were crucial. About the genesis of this relationship can employ the following assumptions: The preparation of the exhibition "common diseases and their control" in 1903 founded Lingner an honorary committee, which included Prof. Richard Pfeiffer (1858 - 1945), who discovered the influenza bacillus and bacteriolysine of collaborated cholera. About Pfeiffer might Lange, the scientific supervisor of the exhibition and director of the Department of Bacteriology, connect to the director of the Hygiene Institute of the University of Bern, Prof. Wilhelm Kolle (1868-1935), was added. Professor Pfeiffer worked together for years with Professor Kolle on the fundamentals of immunity in cholera and typhoid. Even a sudden visit Lingner the Institute of Hygiene, University of Bern seems conceivable, since he visited in preparation for his 1903 exhibition several university institutes, in particular, to collections of pure cultures of bacteria to be considered.

Prof. colleagues acted as Scientific Director of the established in 1898 in Bern, Swiss Serum and Vaccine Institute. A log of the Supervisory Board meeting of the Swiss Serum and Vaccine Institute, 9 January 1909 highlights the cooperation with Lingner [158]. Therefore mediated contacts between colleagues Prof. Lingner and the Swiss Institute. At the instigation of CK were Vgeführt since October 1908, which came in January 1909 for completion. Thereafter, the Swiss Serum and Vaccine Institute has committed itself to support the establishment of the Saxon Serum plant and frees up markets. As head of the serum to be founded Saxon work professor Dr. Otto Heller was used. Heller qualified as a lecturer and was at the Bern University Institute for infectious diseases among active colleagues. His research topics of the trial was one for making a non-infectious vaccine against rabies [193]. Professor Kolle insured against the Swiss Serum works to lead the senior scientific leadership in Dresden for three years. Lingner undertook to pay ten percent per year in net income (minimum: 8,000 dollars) for ten years at the Swiss Serum plant. In addition, Lingner had one lump sum to pay 50,000 marks. Of these, 6,000 marks and two colleagues received from the net income per share 3000 Mark year of activity.

After the contract was Lingner Board Member of the Swiss Serum and Vaccine Institute, Berne. He granted the Swiss Institute a loan of 5,000 francs, time and reason are unknown [41]. Lingner said in February 1909 with the Ministry of the Interior, that he intends "to take equipment for the manufacture and distribution of medicinal Sera" on the road Löbtauer 45th For this purpose he rented from the corresponding shares Gambrinus brewery building. Heller's leadership came under the administration rooms, laboratories, stables for 30 horses for serum collection and cooling, storage, bottling and packaging facilities.

In the years 1909 to 1910 was the establishment of the Saxon Serum Institute of Bakteriotherapie and work on the Löbtauer Str.45. In addition, Lingner tried to obtain the formal approval for the planned production of serum. In addition to the Interior Ministry, the district chief of Dresden and the team had Medizinalpolizei the trade office act.

Lingner in 1910 showed the trade office's intention to open the Dresden Saxon Serumwerk and Institute for Bakteriotherapie. By letter dated July 19, 1910 Office of the tissue Lingner ultimately receives the permission, "... for the production and distribution of Heilseris". On 17 Was registered in October 1911, the Saxon Serum Plant and Institute for Bakteriotherapie as GmbH in the Commercial Register at Amtsgericht Dresden. The Directorate was staffed by Otto Heller and the men appointed as managing directors and Reichelt Bethke, George Seiring also was involved in the management of the company. Lingner did as Chairman of the Board relevant shares. Initial successes achieved, the Saxon Serum Plant with the comprehensive provision of sera and vaccines against cholera and typhoid in the first Balkan war 1912-13. The resulting profits allowed the costly tests to produce a serum for the fermentative cancer detection of cancer. For this purpose, the serum plant invested about 100,000 gold marks. From 1912, a bacteriological-serological investigation resulted in serum plant site including the Aquarius? Chemical reaction for syphilis diagnostics.

The First World War, this intensive research, however, for the time being, as was the front cover of a great need for tetanus serum. Sera were also against diphtheria, dysentery, cholera, gas gangrene and needed Streptound pneumococcal and plague and manufactured. Seiring describes the situation as follows: "The war brought back but other tasks. They had generally expected a short war and therefore not made provisions for a long time. The medical service was mostly in the residue. Would lack e.g. Tetanus serum almost completely. I took over the operational management of the Saxon work, and serum was immediately inoculate 200 horses, which we got from the army command made available to if possible to quickly obtain the important serum. In addition to its own production, the Saxon Serum Plant acquired on behalf of the German army administration sera abroad, it could have used his connections to the Lingner Swiss Serum and Vaccine Institute. After World War II, the Saxon Serum Plant worked primarily in the field

the fight against syphilis, the protein-body therapy and tuberculosis control. According to Lingner's death was paid according to the testamentary disposition of the employees and workers of the Saxon Serumwerk one-time cash grant in the total height of about 6,700 marks. Lingner's shares could be sold in February 1917 with a profit of 30,000 marks. After the conversion to a stock corporation in 1922 in the sense Lingner, a representative of the state government of Saxony has been delegated to the Supervisory Board, to secure the interests of the community in the fight against endemic diseases. Relations with the Swiss Serum and Vaccine Institute remained with the appointment of its director, Paul Gardinaux exist in the board of the Saxon Serum plant